

Curriculum Vitae

INFORMAZIONI GENERALI

Cognome e nome: Tomassetti Sara

ISTRUZIONE E FORMAZIONE

2000 - Laurea in Medicina e Chirurgia presso l'Università degli Studi di Bologna (2/1/2001), con voto 110 e lode. Titolo della tesi "Il clamp euglicemico nella steatoepatite non alcolica". Pubblicata in Diabetes 2001; 50:1844-50; Lancet 2001; 358:893-4.

2001 – Abilitazione professionale presso Università degli Studi di Bologna (1/6/2001) ed **iscrizione all'Albo** dei Medici Chirurghi ed odontoiatri di Forlì, del 4/9/2001, Num 4241.

2004 – Specializzazione in Malattie dell'Apparato Respiratorio (27/10/2004) presso l'Università degli Studi di Modena, con voto 30/30. Tesi realizzata durante research fellowship (da 03/2003 a 04/2004) presso la **Respiratory and Crit Care Med, Harvard University, Brigham and Women's Hospital, Boston USA**. Titolo della tesi: "A possible immunological role for dendritic cells in chronic obstructive lung disease pathogenesis: the antigen presentation process may be influenced by an impairment of their migratory ability caused by MMP12 and others MMPs/MMPs inhibitors expression imbalance". Pubblicata in J Immunol. 2008 May 15; 180(10): 6623–6628.

2014 - Abilitazione professionale Australiana presso l'AMC (Australian Medical Council) con validità dal 2014 al 2018.

2018 – Abilitazione Scientifica Nazionale II fascia settore concorsuale MED 06/D1, con validità dal 31/10/2018 al 31/10/2024.

22/6/2021 – Abilitazione manageriale per la Direzione delle strutture sanitarie Complesse, Università degli Studi di Bologna.

31/01/2022 - Abilitazione Scientifica Nazionale I fascia settore concorsuale MED 06/D1, con validità dal 31/01/2022 al 31/01/2031.

Formazione post -laurea

2005 – Borsa di studio presso la U.O. di **Pneumologia Interventistica dell'Ospedale di Forlì, IT**, titolo del progetto "Trials clinici per la terapia della IPF".

Dal **2008 al 2015** partecipazione per **un mese all'anno** (Maggio 2008; Settembre 2009; Agosto 2010; Agosto 2011; Maggio 2012; Novembre 2013 e Agosto 2015) al programma formativo Visiting Clinician Program, presso la U.O. di **Respiratory and Crit Care Med della Mayo Clinic, Rochester, MN, USA**.

Agosto 2018, Visiting Clinician at Respiratory and Crit Care Med (Prof. H Collard and B Ley), **UCSF, CA, USA**.

Agosto 2022, Visiting Professor at Respiratory and Crit Care Med (Prof. Naftali Kaminski), **Yale University, CT, USA**.

Servizi svolti

2006 – Contratto di lavoro a tempo determinato presso la U.O. di **Pneumologia Interventistica dell’Ospedale di Forlì**, IT come dirigente medico di I livello, per 38ore settimanali.

dal 2007 al 28/2/2020 - Contratto di lavoro a tempo indeterminato presso la **U.O. di Pneumologia Interventistica dell’Ospedale di Forlì, IT** e poi presso la **U.O. di Pneumologia** dello stesso Ospedale come dirigente medico di I livello, per 38 ore settimanali.

Dal 2/07/2019 al 29/2/2020 conferimento di **incarico professionale di Alta Specializzazione, titolo “Pneumopatie Diffuse Infiltrative”** presso il Dipartimento di malattie dell’Apparato Respiratorio e del Torace della AUSL Romagna, delibera N209 del 2/7/2019.

Dal 1/3/2020 al 15/1/2026 **Direttore della SOD di Pneumologia Interventistica presso l’Azienda Ospedaliero-Universitaria Careggi, Firenze, IT e Professore Associato di Malattie dell’Apparato Respiratorio** presso l’Università di Firenze.

Dal 16/1/2026 **Direttore della UOC di Pneumologia di Rimini e Riccione presso l’AUSL Romagna.**

POSIZIONI FUNZIONALI E COMPETENZE

Dal 1/3/2020 a tutt’oggi Direttore della SOD di Pneumologia Interventistica presso l’Az Ospedaliero-Universitaria Careggi. **Gestione ed organizzazione dell’attività specifica della unità complessa** di Pneumologia Interventistica. Gestione dei **percorsi di Pneumologia Interventistica, reperibilità endoscopica h24 di area vasta e consulenza** in favore del Pronto Soccorso e degli altri reparti ospedalieri (es Med Interne, Med d’Urgenza, Cardiologia e Cardiochirurgia, Rianimazioni ecc). Durante la pandemia COVID-19 attività di **consulenza e gestione pneumologica dei pazienti acuti presso le terapie intensive, il Pronto Soccorso e le degenze COVID**. Attività di consulenza e gestione pneumologica dei pazienti con **patologie respiratorie acute e croniche** (e.s. insuf respiratoria, patol ostruttive, restrittive, neoplastiche). **Organizzazione dei percorsi per le patologie pneumologiche acute** e tempo dipendenti, con particolare riferimento alle patologie di pertinenza interventistica. Attività di **endoscopia e reperibilità endoscopica** per procedure complesse urgenti. Implementazione del **teleconsulto** per la creazione di percorsi ospedalieri integrati con il territorio di afferenza. Gestione della **lista operatoria e delle liste d’attesa** per le prestazioni ambulatoriali e broncoscopiche. Partecipazione al progetto CaRED (Careggi Re-Engineered Discharge) di miglioramento della **comunicazione ospedale, territorio e MMG**. Conduzione di progetti europei finalizzati a a migliorare la diagnosi, **la gestione ospedaliera e territoriale del post-COVID** (es. COMUNICARE, progetto di **telemedicina** per il follow-up; PCOILS progetto multicentrico di follow-up postCOVID; BAL nella diagnosi di COVID-19). Promozione di percorsi di **appropriatezza** diagnostica e terapeutica EBM in ambito di pneumologia interventistica, con esperienza nell’ausilio degli strumenti di **gestione del rischio clinico** (GRC Regione Toscana) per garantire la sicurezza, il flusso informativo e orientare la pratica verso l’appropriatezza basata su linee guida e **Evidence Based Medicine**. Panelist e coautrice delle **linee guida internazionali** sulla criobiopsia e capofila della task force AIPO-ITS per la stesura delle **linee guida nazionali** sulla stadiazione ecoendoscopia del mediastino. Estesa esperienza di **lavoro in ambiente multidisciplinare**: GOM (gruppo pneumo-oncologico), GIM (gruppo multidisciplinare mal rare), incontri strutturati pneumologici-anatomopatologici, ambulatori congiunti (es pneumo-reumatologico; pneumo-oncologico).

Partecipazione ed implementazione di **PDTA multidisciplinari e mutiprofessionali** (es. COVID-19, Micobatteriosi, Pneumopatie Inf Diffuse). Pluriennale esperienza professionale nella diagnosi e stadiazione del **tumore polmonare**.

Dal 2007 al 29-2-20 dirigente medico di I livello presso la UO di Pneumologia (Dir. Prof. V. Poletti) dell'Ospedale GB Morgagni, Forlì, IT. **Attività clinica assistenziale e gestione di tutte le patologie respiratorie acute e croniche, inclusa insuff respiratoria e ventilazione non invasiva. Attività pneumologica di degenza, Day Hospital, Day Service, ambulatoriale e broncoscopica** (sia broncoscopia rigida che flessibile), comprensiva di turni di pronta reperibilità endoscopica (circa 8-10 turni/mese). Attività di consulenza pneumologica per tutte le U.O. dell'Ospedale di Forlì. Attività specialistica ambulatoriale e di Day Service e Day Hospital dedicata alle Malattie Rare Polmonari, tra cui prevalentemente le Pneumoptie Infiltrative Diffuse, per l'area Vasta Romagna con bacino d'utenza nazionale (circa 75% di pazienti extra regione). Il centro riconosciuto come centro di riferimento per le malattie rare polmonari sia a livello Regionale (delibera Regione ER del 09/2017), che internazionale (rete europea delle malattie rare polmonari ERN-LUNG, dal 2016).

Attività come **medico di reparto** presso la **degenza ordinaria della U.O. di Pneumologia** dell'ospedale GB Morgagni di Forlì con casistica comprendente tutti gli ambiti pneumologici (incluse: oncologia, infettivologia e tubercolosi, insuff respiratoria e ventilazione non invasiva, BPCO, Asma, pneumopatie infiltrative diffuse).

Attività multidisciplinari: partecipazione al Gruppo Interdisciplinare Pneumo-Oncologico ed ai meeting settimanali sulle malattie rare polmonari (MDT ILD Pneumologia di Forlì). Organizzazione dei **percorsi integrati multidisciplinari aziendali** (**percorso AIMART** procedura Aziendale pubblicata in 12/2018).

La casistica endoscopica come primo operatore dal 2008 al Giugno 2025 consiste in: 1252 broncoscopie rigide sia diagnostiche che operative (disostruzioni e/o posizionamento di protesi tracheo-bronchiali, N= 78 nell'ultimo quinquennio); 420 biopsie/aspirati linfonodali mediastinici (TBNA, EBUS-TBNA, EUS-FNA) e 38 criobiopsie mediastiniche EBUS guidate (metodica di alta innovazione, principal investigator e centro coordinatore di uno studio prosepittico internazionale); 491 biopsie transbronchiali con criosonda (il centro di Forlì è stato pioniere a livello internazionale, la tecnica è stata poi importata da me al centro di Firenze) e criobiopsie transbronchiali con navigazione elettromagnetica (il centro di Firenze insieme al centro di Aarhus è promotore di un innovativo studio multicentrico internazionale su questa metodica altamente innovativa). Oltre 1.500 broncoscopie flessibili, biopsie transbronchiali con sonda convenzionale, con EBUS radiale, lavaggi broncolaveolari, broncolavaggi e broncospirazioni; 88 toracoscopie mediche; 1 lavaggio polmonare totale per la proteinosi alveolare presso il centro di Forlì.

Specifici ambiti di autonomia e competenza professionale

1. 2009-2014 Referente del percorso "Fibrosi Polmonare Idiopatica" presso la U.O. di Pneumologia dell'Ospedale GB Morgagni di Forlì
2. 2015 al 2018 – Referente dell' Ambulatorio AIMART (Interstiziopatie Malattie Rare e Trapianto) presso la U.O. di Pneumologia dell'Ospedale GB Morgagni di Forlì.
3. Da 12/2018 al 28/2/2020 – Referente del percorso aziendale "AIMART" per le pneumoptie infiltrative diffuse per l' Azienda Area Vasta Romagna.

4. Dal 2019 al 28/2/2020 – titolare di **alta specializzazione** in Malattie Rare Polmonari, presso la U.O. di Pneumologia dell’Ospedale GB Morgagni di Forlì.
5. Dal 1/3/2020 **Direttore di Unità Complessa** di Pneumologia Interventistica presso l’Az Ospedaliero-Universitaria Careggi, Firenze

Innovazioni in ambito clinico

ILD-database.

Pulmonary Unit; GB Morgagni Hospital (2005-2016)

In collaborazione con ing biomedica ho sviluppato il database e raccolto i dati di 780 pazienti IPF (dal 2002 al 2018), e di oltre 200 ILD (dal 2013 al 2016). L'obiettivo principale era quello di creare uno strumento di semplice utilizzo nella pratica clinica che permettesse di raccogliere dati immediatamente fruibili a scopo di ricerca. Il database è stato utilizzato per raccogliere in modo prospettico tutti i dati clinici dei pazienti. E’ stato ampiamente ed efficacemente utilizzato per facilitare gli arruolamenti nei trial clinici. Il database ha permesso la raccolta di dati che sono stati utilizzati in numerose pubblicazioni scientifiche (riportate in sezione pubblicazioni). I dati sono stati presentati a congressi nazionali e internazionali (riportato nelle sezioni relative alla partecipazione ai congressi).

Innovazioni tecnologiche

Criobiopsia transbronchiale (2011-oggi)

Con il gruppo di Forlì ho contribuito all’introduzione a livello internazionale della **criobiopsia transbronchiale diagnostica nelle pneumopatie infiltrative diffuse**. E’ **la più importante innovazione in campo diagnostico-endoscopico degli ultimi anni**. Insieme al gruppo diretto dal Prof. Poletti ho prodotto il maggior numero di lavori scientifici presenti in letteratura sull’argomento ed ho partecipato alla stesura delle linee guida internazionali sulla criobiopsia nelle ILD (pubblicate nel 2022). I risultati dei miei studi sono stati presentati in numerosi congressi internazionali (es ERS e ATS dal 2012 ad oggi, presentazioni orali e sessioni di discussione poster) e pubblicati su riviste peer reviewed con elevato IF (riportato nella sezione relativa alle pubblicazioni).

Dal 2020 ad oggi ho importato la metodica a Firenze e studiato **nuove applicazioni della criobiopsia per la diagnosi del nodulo polmonare periferico** (principal investigator di studio prospettico randomizzato e multicentrico sulla combinazione crio e broncoscopio ultrasottile, “thin ice” trial). Sono inoltre coinvolta come centro partecipante nello studio multicentrico Danese (Aarhus University) sull’utilizzo della **navigazione EM come guida** per la criobiopsia.

Criobiopsia Transbronchiale Mediastinica (2022-oggi)

Presso la Pneumologia Interventistica di Careggi, Firenze, ho introdotto l’innovativo approccio criobiopsico al mediastino che ha sostituito la più invasiva mediastinoscopia anche nella diagnosi di patologie complesse come tumori rari, linfomi e patologie granulomatose. Sono attualmente PI e centro coordinatore di uno studio prospettico, randomizzato, controllato,

multicentrico internazionale che valuta questa metodica (protocollo “THE CROWN”).

Toracosopia Medica
(2007-oggi)

Toracosopia viene utilizzata sia nelle patologie pleuriche neoplastiche che non neoplastiche. I risultati della toracosopia medica per il trattamento dell'empima sono stati riportati con il nostro gruppo di Forlì presso la European Respiratory Society nel 2011 e pubblicati (vedi sezione pubblicazioni). Dal 2020 ho importato tale tecnica presso la Pneumologia Interventistica di Careggi, Firenze.

EUS/EBUS; (2007-oggi)

Il centro di Forlì è stato uno dei primi centri in Italia ad adottare la stadiazione medistinicale combinando l'uso di EBUS ed EUS. Esperienza riportata a congressi nazionali ed oggetto di lavori scientifici (vedi sezione pubblicazioni). Sono **capofila della task force sulle linee guida nazionali per la stadiazione ecoendoscopica del mediastino**. In fase di sperimentazione l'utilizzo della criosonda 1.1 per la **criobiopsia mediastinica EBUS guidata** (principal investigator di studio prospettico randomizzato e multicentrico “the crown” trial).

TELEMEDICINA
(02/2023-12/2024)

Conduzione di progetto europeo “COMUNICARE”, progetto di **telemedicina** (DRAGON consortium) finalizzato a migliorare la **gestione ospedaliera e territoriale post dimissione del COVID-19**.

Capacità e competenze relazionali ed ORGANIZZATIVE

- **Master di formazione in formazione manageriale per la Direzione di Strutture Sanitarie Complesse**, Università degli Studi di Bologna, AA 2020/2021
- Dal 2020 ad oggi, **direzione di unità operativa complessa** di Pneumologia Interventistica presso l'Az Careggi, Firenze. **Organizzazione di percorsi assistenziali** per le patologie respiratorie e di **percorsi di consulenza** per pronto soccorso ed altri reparti. **Gestione del percorso emergenza urgenza di area vasta e gestione delle liste operatorie**. Partecipazione a progetti di miglioramento della **comunicazione ospedale, territorio e MMG** (es progetto CaRED - Careggi Re-Engineered Discharge-; COMUNICARE, progetto di telemedicina).
- Dal 2020 ad oggi, esperienza nella **gestione delle criticità relazionali** in collaborazione con il centro di riferimento regionale per le criticità relazionali (CRCR Toscana, Direttore dr.ssa Belloni). Durante il quinquennio 2020-2025, la gestione della SOD di Pneumologia Interventistica di Careggi, Firenze, ha comportato la risoluzione di problematiche interne preesistenti complesse, tra cui la gestione dei conflitti tra il personale medico e medico-infermieristico. L'implementazione di strategie di comunicazione efficace e la promozione di un ambiente di lavoro sereno hanno permesso il superamento delle criticità interne e il miglioramento dell'efficienza operativa della struttura.

- Partecipazione in qualità di discente a **corsi manageriali** (sda bocconi , dal 11/2018 a 03/2019) ed a **corsi di comunicazione** (diamo respiro alle parole, edizione 2017-2018).
- **Responsabile scientifico, relatrice e tutor in corsi di comunicazione e relazione medico-paziente sia nazionali che internazionali** (Respirare e comunicare , Forlì, Marzo 2018; Respirare e comunicare , Forlì, Marzo 2019, AIR meeting, Munich, Germany, Novembre 2018; Un approccio globale, corso FAD, Forlì 05/2019). Coautrice di progetto editoriale dal titolo “Diamo respiro alle Parole” in corso da 03/2019. Primo autore di lavoro scientifico sulla comunicazione medico paziente nella fibrosi polmonare idiopatica (PMID: 34744429).
- **Coordinamento di attività del gruppo di lavoro** sulle Malattie Rare polmonari dal 2009, percorso ufficializzato nel 2015 e poi ampliato a tutta l’ASL Romagna nel 2018, comprendente 6 presidi Ospedalieri (Ravenna, Rimini, Lugo Cesena e Forlì, Faenza; Procedura AIMART)
- Attiva partecipazione ad attività di **formazione nel campo della comunicazione medico-paziente e per le associazioni pazienti** in particolare per l’Associazione Morgagni Malattie Polmonari (Forlì), di cui sono socia fondatrice, e per l’EU-IPF (rete europea pazienti affetti da IPF). **Responsabile scientifico ed organizzativo** di eventi annuali di educazione alla comunicazione medico-paziente supportati dall’associazione AMMP:
 - 14/09/2014 “ Il rinforzo della trama I ed”, Fratta Terme , FC, IT
 - 25/10/2015 “ Il rinforzo della trama II ed”, Fratta Terme , FC, IT
 - 12/3/2017 “ Il rinforzo della trama IIIed”, Fratta Terme , FC, IT
 - 15 Marzo 2018 “Respirare e Comunicare”, Forlì, IT
 - 8 Marzo 2019, “Respirare e Comunicare”, Forlì, IT
- Partecipazione in qualità di relatore ad eventi nazionali organizzati dalle **Ass Pazienti o altri enti**:
 - 17-18 October 2024. FIMARRP, Napoli. Lecture: Anomalie interstiziali polmonari: cosa fare
 - 31 Maggio 2025. Santa Sofia, FC, IT. Il paziente e la cura. Lecture: Il paziente nei processi di cura.
 - 3 giugno 2025. Roma, IT. Conferenza stampa al Senato della Repubblica. Le fibrosi polmonari un bisogno di salute pubblica insoddisfatto. Intervento su: la diagnosi precoce.

ATTIVITÀ E PRODUZIONE SCIENTIFICA

Attività di ricerca clinica

Trials internazionali finalizzati alla valutazione della risposta ai nuovi trattamenti farmacologici delleILD ed in particolare dell IPF (inclusi farmaci antifibrotici come Nintedanib e Pirfenidone, farmaci biologici, immunomodulanti). Numerosi progetti di ricerca volti alla fenotipizzazione e alla definizione di indicatori clinici di prognosi delle malattie rare polmonari, tra cui la IPF, IPF associata a tumore polmonare, NSIP, pneumopatie cistiche, pneumotossicità da farmaci, bronchioliti, interstizioptie familiari. Progetti di ricerca volti a valutare la fattibilità, la sicurezza e l'accuratezza diagnostica di procedure innovative per la diagnosi delleILD, in particolare la criobiopsia. Partecipazione a documenti di consenso e linee guida internazionali. Attualmente capofila delle linee guida nazionali per la stadiazione ecoendoscopica del mediastino.

Collaborazioni con enti/istituti di ricerca internazionali:

- USA: Mayo Clinic, Rochester, MN (Prof. J.H. Ryu); Mayo Clinic, Scottsdale, AZ (Prof. T.V. Colby); IPF Global collaborative IPF network, Denver, CO (Prof. D. Schwartz); UCSF, San Francisco, CA (Prof. B. Ley e Prof. H. Collard), Yale University, CT (Prof. N Kaminski).
- UK: Royal Brompton Hospital, London (Prof. AU Wells)
- Germania: Essen Klinikum Universität Pneumologie (Prof. U Costabel)
- Danimarca: Aarhus University (Prof. E Benstrup)

Affiliazioni a società scientifiche:

- ERS
 - dal 2010 a tutt'oggi – membro European Respiratory Society
 - dal 2013 al 2017 - ERS RESPIRE3 Marie Sklodowska-Curie Fellowship Evaluation Committee, Reviewer
 - 2021 a tutt'oggi commissario ERS per la valutazione delle linee guida internazionali (**ERS guidelines working group**).
 - Dal 2022 a tutt'oggi **Chair Publication Committee e membro dell'esecutivo**.
- AIPO-ITS
 - dal 2012 a tutt'oggi – membro AIPO – Ass Italiana Pneumologi Ospedalieri
 - 10/2013-10/2017 - **Responsabile GdS** Pneumopatie infiltrative diffuse e patologia del circolo polmonare, AIPO – Ass Italiana Pneumologi Ospedalieri
 - Dal 2022 a tutt'oggi – **membro dell'Esecutivo**
- 2021 a tutt'oggi membro e **Delegato Nazionale EABIP** (Soc Europea di Broncologia)
- 2022
 - a tutt'oggi membro ATS (American Thoracic Soc)
 - 2022 comitato valutazione abstract ATS

Premi e Riconoscimenti

6-Dec- 2010	Robalo Cordero Award	26th Congress of Portuguese Resp Soc, Coimbra, Portugal	Research Project : “IPF: from environment to genetic”
7-Jun-2013	Poster Award	6th International WASOG Conference in Paris	Poster title “The diagnostic role of TBLC in the MD of IPF”.

14-Feb-2018	Best publication 2018 Award	Area Vasta Romagna	Publication title “Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis” AJRCCM 2016
-------------	-----------------------------	--------------------	--

Attività editoriale

1. Editor in Chief:

- a. 2018-currently, Sarcoidosis Vascular and diffuse lung disease journal

2. Associate Editor:

- a. 2021-currently, Respiratory Research journal

3. Section Editor:

- a. 2021-2022, Current Opinion Pulmonary Medicine journal, Interventional Pulmonology Section.

4. Reviewer:

- a. 2013, Human Immunology
- b. 2013-currently, BMC Pulmonary Medicine
- c. 2014-currently, Respirology, Respiratory research,
- d. 2015-currently, European Respiratory Journal, Case Report in Pulmonology,
- e. 2016-currently, Chest, Therapeutic Advances
- f. 2018-currently, Journal of Thoracic Diseases, European Respiratory Review, Canadian Respiratory Journal
- g. 2019-currently, AJRCCM, Int J of tuberculosis and lung diseases.
- h. 2020-currently, Mayo Clinic Proceedings, E-Biomedicine journal
- i. 2020-currently Annals American Thoracic Soc journal
- j. 2020-currently Orphanet Journal of Rare Diseases
- k. 2021-currently The Lancet Respiratory Medicine
- l. 2024-currently AJRCCM

Attività didattiche e formative

Professore a contratto per L'università Politecnica delle Marche, AA 2018-2019

Professore Associato di Malattie dell'Apparato Respiratorio dal 1/3/2020 presso l'Università degli Studi di Firenze.

Attività didattica istituzionale

- Università Politecnica delle Marche, incarico annuale, Dip Scienze Biomediche e Sanità Pubblica, Master Universitario II livello in Pneumologia Interventistica, AA 2018-2019, titolo della docenza “Il BAL: tecnica, indicazioni e risultati” svolto in data 4 Giugno 2019 dalle ore 9.00 alle ore 11.00.
- Università di Firenze, docente ai seguenti corsi dal 1/3/2020 a tutt'oggi:

- CdL Medicina e Chirurgia, B027971 (B120) - ATTIVITA' FORMATIVE PROFESSIONALIZZANTI V ANNO 2
- CdL Med dello Sport, B027849 (B185) - MODULO: MALATTIE DELL'APPARATO CARDIO-RESPIRATORIO
- CdL Medicina e Chirurgia, B027908 (B120) - MODULO: REUMATOLOGIA
- CdL Medicina e Chirurgia, B027916 (B120) - MODULO: MALATTIE APPARATO RESPIRATORIO I
- Master di II livello, Competenze in Broncoscopia e Pneumologia Interventistica per Infermieri ed Operatori Sanitari
- CdL in Tecniche di Neurofisiopatologia, B026590 (B202) - MODULO: NEUROFISIOPATOLOGIA PER LA PATOLOGIA RESPIRATORIA

Attività didattica presso Università all'estero

1. 24 May 2012. Developmental Pulmonology Laboratory Research. Department of Pediatrics, S Francisco General Hospital, UCSF, CA, USA. Genetic determinants of Familial Pulmonary Fibrosis.
2. 16 March, 2016. Respiratory and Critical Care Med. Mayo Clinic, AZ Transbronchialcryobiopsy in ILD, overview and update
3. 16 March, 2016. Respiratory and Critical Care Med. Phoenix Hospital, AZ Transbronchialcryobiopsy in ILD, overview and update.
4. 27 Agosto, 2018. Respiratory and Critical Care Med. UCSF, CA, USA. Transbronchial cryobiopsy.
5. 22 febbraio 2023. Yale PCCSM Grand Rounds, CT, USA. Title "Novel Frontiers for Transbronchial Cryobiopsy in the post-COVID Era".
6. 10 Giugno 2025. John Hopkin's University, Baltimore, Maryland, USA. Transbronchial cryobiopsy course.

Relatore o correlatore delle seguenti tesi:

1. Co-chair: 9 July 2021, Dr.ssa Meliante Laura Antonia, Florence School of Medicine, "The role of BAL in the diagnosis of SSc", 110/110 summa cum laude e menzione.
2. Chair, 6 Oct 2021, Dr. Fanuzzi Michele, Sport Sciences, Florence University. Title: " Pulmonary hypertension and physical exercise." 98/110.
3. Chair, 24 Nov 2021, Dr.ssa Biadene Giulia, Respiratory Medicine, Florence University, Title: "Multidisciplinary diagnosis of COVID-19 using BAL as diagnostic gold standard". 110/110 summa cum laude and honor.
4. Chair, 10 Jan 2022, Dr. Leonardo Gori, Respiratory Medicine, Florence University, Title: "Clinical-radiologic and pathologic correlations of post COVID-19 ILD". 110/110 summa cum laude and honor."
5. Chair, 8 June 2022, Dr. Stefania Ferraro, Medicine, Florence University. Title: "Evoluzione da 6 a 12 mesi delle alterazioni interstiziali post-COVID-19". 109/110.
6. Chair, 2 Nov 2022, Dr Giuntoli Leonardo, Respiratory Medicine, Florence University. Title: "The ThinICE protocol: combination of cryobiopsy and ultrathin bronchoscopy for the peripheral lung nodule." 110/110 cum laude and honor.
7. Chair, 2 Nov 2022, Dr Ciani Luca, Respiratory Medicine, Florence University. Title: "Role of BAL in COVID-19 patients: a prospective multicentre study" 110/110 cum laude and honor.

8. Chair, 8 June 2022, Dr. Stefania Ferraro, Medicine, Florence University. Title: “Evoluzione da 6 a 12 mesi delle alterazioni interstiziali post-COVID-19”. 109/110.
9. Chair, 16 Sept 2022, Dr. Guidotti Sandro, Sport Sciences, Florence University. Title: Ruolo della riabilitazione nella BPCO.
10. Chair, 13 oct 2022, Dr. Ghirardi Matteo, Sport Sciences, Florence University. Title: Asma ed esercizio fisico.
11. Chair, 20 Dec 2022, Dr. Potenza Francesco, Medicine, Florence University. Title: “Fattibilità dell’approccio combinato criobiopsia e broncoscopio ultrasottile per la diagnosi del nodulo solitario periferico”. 110/110 cum laude.
12. Chair, 5 July 2023, Dr Giulia Caterina Papa, Medicine, Florence University. Title: “Evoluzione clinico-radiologica delle pneumopatie infiltrative post-COVID-19.”
13. Chair, 30 January 2024, Dr. Paolo Fandelli, Medicine, Florence University. Title: “Transbronchial Mediastinal Cryobiopsy , a feasibility study”.

Altre attività accademiche nazionali:

1. Consulente esterno: Marzo 2019, Dr.ssa Piera Soggio, tesi di PhD in Experimental and Regenerative Medicine”, Univesità degli Studi di Foggia, IT
2. Correlatrice: Maggio 2019, Dr.ssa Irene Cardillo, tesi di Specializzazione in malattie dell’Apparato Respiratorio dal titolo “La Fibrosi Idiopatica: nuovi predittori di sopravvivenza”, Università degli Studi di Palermo.
3. Tutor: Luglio 2016, Dr.ssa Dora Nicotra, tesi di Specializzazione in malattie dell’Apparato Respiratorio dal titolo “La Fibroelastosi Peluroparenchimale e i suoi mimickers”, Università degli Studi di Catania.
4. Correlatrice: 9 Luglio 2021, Dr.ssa Meliante Laura Antonia, tesi di laurea in meidicina e Chirurgia, “The role of BAL in the diagnosis of SSc”, Università degli Studi di Firenze, 110/110 lode con menzione.

Altre attività accademiche internazionali:

1. 25 Maggio 2023. Opponent for the Doctoral Program in Clinical Research Helsinki University. Helsinki, Finland. Dissertation title “Recovery from severe COVID-19”. Discussant Anna Lindhal.

Altre attività didattica integrativa

- 18 Maggio 2010 La gestione dell’ossigenoterapia nel paziente con IPF in fase avanzata, lezione rivolta a medici ed infermieri di pneumologia e cure palliative. Hospice, Forlimpopoli, FC, IT.
- 3-5 Giugno 2014, Perceptorship. International training program for chest physicians on IPF . GB Morgagni Hospital, Forlì, Italy
- 13-15 Ottobre 2014, INSIDE IPF. National training program for chest physicians on IPF GB Morgagni Hospital, Forlì, Italy
- 20-22 ottobre 2014 Perceptorship. International training program for chest physicians on IPF. GB Morgagni Hospital, Forlì, Italy
- 11-12 Novembre, 2014 Global internal train the trainer meeting, for pharma industry representatives, Frankfurt, Germany.
- Novembre -Dicembre 2015, “In-Hospital” and “Tutorship” programs, for pharma industry representatives GB Morgagni Hospital, Forlì, IT
- 4 Novembre 2015, “Regional Lab”, Forlì, FC, IT. Educational program for pharmacists. GB Morgagni, forlì, IT
- 15 Dicembre 2015, “Call Simulation”, Educational program for pharmacists. Bologna, IT

- 12-14 Gennaio 2016 In-Hospital” program for pharma industry representatives, GB Morgagni Hospital, Forlì, IT. 3 May. Lezioni: “Il profilo clinico della IPF; 4 May “La terapia della IPF; 25 May “La criobiopsia polmonare”
- 3-4 e 24-25 May, 2016 In Hospital Meeting: IPF Excellence. Corso internazionale per pneumologi. GB Morgagni Forlì, IT.
- 23-25 Novembre 2016, Perceptorship. International training program for chest physicians on IPF. GB Morgagni Hospital, Forlì, Italy
- Sett-Dicembre 2021. Roche perceptorship. International training for pharma representatives, 6 lessons (web) on IPF and innovative drug treatment.
- 28-29 May 2025. Firenze, IT In-hospital. Chair of the event, tutor and lecturer.

Comunicazioni orali a congressi

- **Internazionali:**

1. 24 May 2012 Genetic determinants of Familial Pulmonary Fibrosis. Developmental Pulmonology Laboratory Research Conference. Department of Pediatrics, S Francisco General Hospital, UCSF, CA, USA.
2. 30-Nov-1Dec, 2012, Interactive Clinical Cases. Working together to translate IPF research into practice. European AIR Meeting, Rome, Italy.
3. 5June2013, The role of TBLC in the multidisciplinary diagnosis of IPF. Wasog Meeting. Paris, France*Recipient of the Wasog Best Poster Presentation Award
4. 9-10 June 2014 The role of TBLC in MD diagnosis of IPF. Transbronchial lung cryobiopsy. ERS endorsed course. Ravenna, Italy
5. 6-10 Sept 2014, Patient cases: the multidisciplinary approach Evening Symposium : How to diagnose and treat IPF: learnings from clinical and real-world experience ERS annual congress. Munich. Germany
6. 27 Sept, 2015 “Educational skills workshop: EW10 Radiological – pathological correlations for clinicians”; Workstation 2: Interstitial fibrosis; ERS annual Congress, Amsterdam, Netherlands
7. 27 Nov, 2015 “MDT case in Session 2: Striving for early IPF diagnosis” Air Meeting International. Prague, CZ
8. 12 March, 2016 Transbronchialcryobiopsy in ILD, overview and update, presented with Prof. T.V. Colby, Mayo Clinic ,AZ USCAP Annual Meeting, Seattle, WA, USA
9. 16 March, 2016 Transbronchialcryobiopsy in ILD, overview and update. Pulmonary Fellow Wednesday Morning Meeting, Mayo Clinic ,AZ
10. 16 March, 2016 Transbronchialcryobiopsy in ILD, overview and update Pulmonary Meeting, Phoenix Hospital, AZ
11. 8-11 May, 2016 “Multidisciplinary diagnosis” World Congress for Bronchology and Interventional Pulmonology. Florence, IT
12. 1-4 June, 2016 8th international WASOG conference. Gdnask, PolandTransbronchial cryobiopsy in diffuse parenchymal lung diseases. Case presentation clinical round
13. 2-7 Sept 2016 ERS Annual Congress. London, UK.
 - a. Skills workshop: SW20 Radiological-pathological correlations for clinicians. Workstation 2: Interstitial fibrosis
 - b. Year in review: Clinical year in review Diffuse parenchymal lung disease. Session 51
14. 17-19 Nov, 2016 “ BLC for the diagnosis of IPF” Advancing IPF Research (AIR) Educational Meeting. Vienna.

15. 22 Feb, 2016 “ Transbronchial lung cryobiopsy in idiopathic interstitial pneumonia: state of the art “ Workshop: a new era for IP. Leuven, Belgium
16. 23 Feb, 2016 “Clinical diagnostic value of bronchoscopy in IIP “ Interventional Pulmonology symposium. Leuven, Belgium
17. 9-13 Sept, 2017. Speaker and tutor: “Skills workshop: SW20 Radiological-pathological correlations for clinicians. Workstation 2: Interstitial fibrosis. ERS, Milan, IT
18. 10-11 Oct, 2017. Course: Transbronchial cryobiopsy in DLPD “ endorsed by ERS, Ravenna, IT
 - a. “Cryo-TBB vs awakened VATS
 - b. “IPF therapy : the future
 - c. Chair of the session: “Technical notes. TBCB: how should be done”
19. 15-18 Nov, 2017. 17° Congresso paulista de Pneumologia e Tisiologia, sao Paulo, Brazil Speaker: “Cryobiopsy and ILD”
20. 14-15 Dec, 2017 Con debate: “IPF should be viewed as a malignancy, based on pathogenesis, biomarker signal and disease behaviour” International summit for ILD, ERICE study group, ERICE, IT
21. 7-9 June, 2018. “Interstitial Lung Abnormalities” WASOG annual meeting, Crete, GR
22. 14-19 Sept, 2018. ERS annual meeting, Paris, FR. Lectures:
 - a. “ Acute Interstitial Lung Diseases”, PG course, September 15
 - b. “Interstitial Fibrosis”, Skill workshop, September 18
 - c. “IPF treatment” , Speakers dinner Roche Brasil, September 16
23. 26-27 Sept, 2018 Lecture: “Nintedanib for IPF treatment” Cryobiopsy International Meeting, Ravenna, IT
24. 11-12 Oct 2018 “NSIP” and clinical cases ILD Network meeting, Lisbona, Portugal (sponsored BI)
25. 17-18 Nov, 2018 “ Difficult communications” Advancing IPF Research (AIR) Educational Meeting. Munich, German
26. 22-24 November, 2018. Think Lung, Bahia, Salvador , Brazil. Lectures:
 - a. “Cryobiopsy:where do we stand and where will we go”
 - b. “the utility of cryobiopsy for the diagnosis of ILDs”
 - c. IPF diagnosis and treatment, panel discussion
 - d. Clinical Cases
27. 15 March, 2019 “Pathologic diagnosis of Idiopathic Pulmonary Fibrosis: Which is the role of the cryobiopsy?” International symposium of ILDs, Barcelona, Spain
28. 27 Sept-1o oct, 2019. ERS Annual Congress, Madrid , Spain:
 - a. Endoscopy Live session on lung transbronchial cryobiopsy in ILDs
 - b. Post graduate course on Pulmonary endoscopy, Cryobiopsy in patients with interstitial lung diseases.
29. 7-9 Nov, 2019. 35th Portuguese Pulmonary Society Annual Congress, Albufeira, Portugal. Lecture title: How to predict progression, when and how should we treat?
30. 15-16 Nov, 2019. AIR Europe, Malmo, Sweden. Lecture title: Examining ILAs and their significance to development of ILD
31. 4 June 2020. ERS web course COVID-19 and the management of Interstitial Lung Diseases patients: challenges and recommendations
32. 18 June 2020, Escubriendo Encognita en el entorno COVID-19, Spain (web). Lecture: COVID-19 and ILD.
33. 20 June, 2020. "Challenges and recommendations in the management of Chronic Respiratory Diseases and the COVID-19 disease” (web). Lecture “Novel data in interventional pulmonology”.

34. 20 June, 2020. International web course (ALAT, ITS, Sociedad Espana, SPPEcc). "Challenges and recommendations in the management of Chronic Respiratory Diseases and the COVID-19 disease" lecture title: "Novel Data in interventional Pneumology".
35. 5-9 Sept, 2020. ERS international congress, on-line:
 - a. Oral poster presentation: Historical eye on IPF: redefining the mortality scenario
 - b. The hot and the cold of interventional pulmonology, oral poster presentation: "Clinical management implications of histologic information provided by lung biopsy in the multidisciplinary evaluation of interstitial lung diseases."
 - c. Lecture: Lung transplant in ILDs
36. 12 Nov, 2020. Albufeira (on-line). FIBROTIC PULMONARY INTERSTITIAL LUNG DISEASES Lecture: Early Diagnosis of Fibrotic Pneumonias and the impact on Clinical Management.
37. 15-16 Nov, 2019. AIR Europe. Malmo, Sweden. "Interstitial lung abnormalities".
38. 26-27 Feb 2021. International meeting pulmonary rare Diseases and orphan drugs, Milan (web). Lecture: "Interstitial Lung Abnormalities: only abnormalities or disease?"
39. 27-28 May, 2021. Romanian National Congress (web). Lecture: "post-COVID-19 ILD".
40. 14-19 May, 2021 ATS (web). Oral Poster Presentations: "PCOILS, preliminary results from a National prospective study on post COVID-19 ILD" and "A pilot study on EM navigation and cryobiopsy in ILDs".
41. 22 may, 2021. World Scleroderma Foundation meeting. Brazil (web). Lecture: "Bronchoalveolar lavage and the biopsy for ILD: respective indications and input".
42. 14-17 July, 2021. Oporto ILD meeting, Portugal (web). Lectures: "Hypersensitivity pneumonitis" and "PPFE".
43. 20 Aug 2021. FUNEF congress, Argentina (web). Lecture: "When and how perform a biopsy in interstitial lung diseases?"
44. 4-8 Sept 2021. ERS international congress (web). Oral presentations: 1. Pro-con debate, title "Antifibrotics in post-COVID-ILD: con". 2. E-poster presentation, title: "Multidisciplinary diagnosis of COVID-19 using BAL as diagnostic gold standard". 3. Oral poster presentation, title. "Post-COVID interstitial lung disease". 4. Endoscopy - advanced techniques: live out of the box, title: "TBLC for ILD".
45. 15-17 Oct 2021. EABIB international congress, Athen (live). Oral presentation: "Utility of bronchoscopy for COVID-19, does it with the trouble?". 2. Chair E-poster session "Imaging training and navigation modalities".
46. 16-17 Sept 2021. Transbronchial cryobiopsy in ILDs, AIPO and EABIP international workshop (web). Lecture title: "The prognostic value of TBLC for the diagnosis of ILD".
47. 1 Dec 2021. Cairo, Egypt (web). Annual Assembly of the Egyptian Scientific Society of Bronchology. Lecture "Cryobiopsy for the diagnosis of ILD, current perspective and real life experience".
48. 17 Dec 2021 World Scleroderma Foundation CSTAR Masterclass on ILD in SSc. Lecture: "BAL in CTD-ILD".
49. 17-18 Nov 2021. ERS virtual school. Chair session ILD diagnosis II.
50. 20 Nov 2021. Japanese National Congress, Kyoto (web). Session: Emerging Talent Symposia 27
Oral presentation: Review of BAL in Interstitial Lung Disease diagnosis.
51. 31 March, 2022. EABIP endoscopy workshop, Cluj-Napoca (web). Lecture: Cryobiopsy in clinical practice.
52. 1 April, 2022. EUSTAR/WSF Systemic Sclerosis Virtual School 2022 (virtual only). Lecture: The role of BAL and lung biopsy in SSc.
53. 2 April 2022. Oporto interstitial Lung Diseases Meeting 2022, Oporto, Portugal (web). Lecture: Pathology of Fibrotic ILD: UIP and beyond.

54. 23 May 2022. International digital symposium: ILD today and tomorrow. Oral presentation: Time to trust TBLC for the diagnosis of ILDs.
55. 26-27 May, 2022. **Chair** and speaker of the international EABIP research seminar: advancing research in interventional pulmonology. Florence, IT. Lecture: Novel frontiers for TBLC.
56. 27-29 June 2022. Chest Congress, Bologna, IT. Thoracic echography hands on session.
57. 15 July 2022. ECR congress. Vienna, Austria (web). Lecture: Do we still need a diagnosis in f-ILDs?
58. 16 July 2022. Singhealth ILd workshop. Lecture: ILD beyond 2022.
59. 18 August 2022. ERS webinar (virtual only). Lecture: Methodology of TBLC international guidelines.
60. 22-23 Sept 2022. ERS endorsed international course on TBLC. Ravenna, IT. Lecture: clinical and prognostic impact of TBLC in ILDs.
61. 25 Sept 2022. Portugese Pulmonary Society Forum. Oporto, Portugal. Lecture: Criobiopsy: state of the art.
62. 6-9 October 2022. EABIP congress. Madrid, Spain. Lecture: TBLC in ILDs and nodules.
63. 8 Nov 2022. TRS respiration 2022. Turkey (web). Lecture: What's new in Sarcoidosis?
64. 14-17 November 2022. WASOG congress. Sibiu, Romania. Lecture. ILA.
65. 29 Nov 2022. Lung cryobiopsy workshop. Ain Shams Hospital, Egypt. Lectures: 1. Bronchoscopic approach to lung nodules. 2. Bronchoscopic approach to ILDs. 3 real life clinical cases.
66. 30 Nov 2022. Egyptian Bronchology Soc Annual Congress. Cairo, Egypt. Lecture: Cryobiopsy, lung and mediastinal approach.
67. 5-6 December 2022. WABIP course. Santiago, Chile. Lectures: 1. TBLC in PID diagnosis. 2. TBLC in the MDT diagnosis.
68. 9 December 2022. Chinese Medical Ass Congress (virtual). Lecture: Interventional pulmonology in COVID-19.
69. 4 March 2022. International Meet on Rare Diseases. Milan, IT. Lecture: ILA a clinical point of view.
70. 9 March 2023. Oporto Congress. Oporto, Portugal. Lecture: Updates in ILDs.
71. 13-16 March 2023. WABIP Workshop Buenos Aires, Argentina. Lectures: 1. Cryobiopsy, indications and technique; 2. Cryobiopsy in ILDs.
72. 15-16 March 2023. 32 Congreso argentino di Broncologia. Buenos Aires, argentina. Opening Lecture: Update on cryobiopsy in ILDs.
73. 28-29 March 2023. ERBER workshop. Paris, France. Lecture: Transmediastinal cryobiopsy.
74. 11-13 May 2023. EABIP congress. Madrid, Spain. Lecture: when to perform endoscopic biopsies in ILDs.
75. 1-2 June 2023. DRAGON Conference. Bruxelles, Belgium (web). Roundtable: cinical networks and trials.
76. 6-7 June 2022. ERS virtual school on sarcoidosis (virtual only). Lecture: the do and don't of lung biopsy in sarcoidosis.
77. 15-16 June 2022. ERBE workshop. Schonfeld, Germany. Lectures: 1. peripheral lung nodal; 2. Centrail airway multimodal approach.
78. 22 June 2022. Egyptian bronchology society course. Alessandria, Egypt (web). Lecture: updates on ILDs.
79. 29 June – 2 July SHARE 3 congress. Heraklion, Greece. Lectures: 1. Genomic classifier for ILDs; 2. ILAs red flags; Pro-con debate: (PRO) IPAF is it a clinical diagnosis?
80. 13 July 2023. Broncho Egypt. Cairo, Egypt. Lecture: transmediastinal cryobiopsy.
81. 10 August 2023, ILD Virtual Multidisciplinary Discussion, Rio De Janeiro Federal University, on-line (sponsored BI).
82. 9-13 September 2023, ERS congress Milan. Sept 12, session on Interventioanl Pulmonology, Freeze, fry or fume. Lecture: "TBLC in ILDs".

83. 18-20 October 2023, PneumoRio, Rio De Janeiro, BR. Lectures: Date: October 18th Room: Auditorium 5 Role: Speaker Lecture title: Transbronchial cryobiopsy and bronchoalveolar lavage - Role in the diagnosis of interstitial lung diseases Presentation time: 16:20-16:40 Date: October 19th Room: Auditorium 3 Role: Speaker Lecture title: In times of progressive pulmonary fibrosis, what is the role of histopathological diagnosis in interstitial lung disease. Presentation time: 12:15-12:30 Date: October 20th Room: Auditorium 2 Role: Speaker Lecture title: Post-COVID Interstitial Lung Disease - Preliminary Results of the DRAGOM Study Presentation time: 09:00-09:30
84. 24-27 Oct 2023. Post Pandemic Advances in Pulmonary Medicine. Annual Congress of the Egyptian Soc of Chest Diseases, Tuberculosis. Lecture on line, title: TBLC in ILDs.
85. 9-10 November 2023. 39° Congresso Nazionale Soc Portoghese di Pneumologia. Algarve, Portogallo. Lecture: Interstitial Lung Abnormalities how to proceed and monitor.
86. 14-15 November 2023. ERS Virtual academy on interstitial lung diseases. Chair.
87. 12-14 January 2024. 4TH International Symposium on Interstitial Lung Disease in Rheumatic Diseases. Webinar. Lecture: ILA and CTDs: a new kid on the block?
88. 19-20 February 2024. Erbe INTERVENTIONAL PULMONOLOGY Workshop. Medizin im Grünen, Wendisch Rietz, Germany. Tutor for basic and advanced hands on sessions. Lectures: TBLC for PLN and mediastinum. Multimodal applications for central airway.
89. 7-8 March 2024, Oporto, Portugal. XXXI North Pneumology Congress. Lecture: Cryobiopsy: is there a place beyond interstitial lung diseases?
90. 3-6 April 2024, Oporto, Portugal. 13th Oporto Interstitial Lung Diseases Meeting. Lectures: 1) Why histology is crucial for a precise splitting of fibrotic ILDs; 2) Interstitial Lung Abnormalities- when to move to the diagnosis?
91. 15 April 2024. ERS WEB Seminar. 3rd edition of ERS ALAT joint webinar. Lecture: Lung Cancer in patients with Fibrosing ILDs
92. 11 May 2024. ESTI, Rome, IT. Lecture: ILA: what's new?
93. 19 May 2024. ATS, San Diego, USA. Lecture: Therapeutic Options for Patients with CPFE.
94. 4-5 June 2024. ERS Sarcoidosis Academy. Milan, IT. Lecture: The do's and don'ts in biopsy of suspected sarcoidosis.
95. 7-11 September 2024. ERS Annual Congress. Chair oral sessions: 1) Clinical Guidelines; 2) Clinical Cases.
96. 12-16 October 2024. Athens, Gr. ICLAF congress. Lecture: ILAs time for action-Diagnosis and management
97. 28-29 October 2024. Germany. ERBE hands on course. Tutor and lecture: cryoBx applications.
98. 21 November 2024. St Gallen, Switzerland. ILD symposium. Lecture: Tissue – when and how?
99. 27-28 November 2024. ERS virtual academy on ILD. Chair and Lungs on fire session discussant.
100. 9 January 2025. Groten Zal, Woorden, NL. Prof. dr. Jules van den Bosch Symposium XIII. Lecture: Early pulmonary fibrosis: a guidance in the era of interstitial lung abnormalities.
101. 13-14 March 2025. Leuven, Belgium. REFLECTION IIIed. Lecture: ILA.
102. 5-6 June 2025. Oporto, Portugal. 14th Oporto ILD meeting. Lectures: 1) Progressive pulmonary fibrosis in CTD-ILD: early diagnosis and management (June 5th); 2) IPF survival: do we have the precise scenario in the antifibrotics era? (June 6th)
103. 9 June 2025. Baltimore, USA. John Hopkins University. Transbronchial and EBUS Guided Cryobiopsy: Mastering the Technique. Tutor.
104. 18 June 2025. Thessaloniki, Gr. Cryobiopsy course. Tutor and Lecture: MDT Meetings in the Diagnosis and Management of Diffuse.

105. 20 June 2025. Thessaloniki, Gr. Panhellenic National Congress. Lecture: Novelty in ILD diagnosis and management.

• **Nazionali:**

1. 20-22 Oct 2008 Usual Interstitial Pneumonia Advanced Course. HRCT of the thorax. Arezzo
2. 2-5 Dec 2009, AIPO National Pulmonary Congress, Milan Convention Center, ITALY:
 - a. Idiopathic Pulmonary Fibrosis
 - b. Anti TNF treatment for ILDs-related to connective tissue diseases.
 - c. Birt Hogg Dubè Syndrome
3. 19 June 2009, Aggiornamenti in Med Interna. Bari, IT. Title: Diagnosis of ILDs
4. 15-17 April 2010, Corso teorico-pratico. Interstiziopatie polmonari. Gubbio, IT. Lectures:
 - a. Clinical profile of diseases with HRCT Reticular Patterns
 - b. Clinical Cases
5. 10-12 May 2010 Idiopathic Pulmonary Fibrosis ERS scientific group on DPLD post graduate course, PneumoTrieste, Trieste, ITALY
6. 25-26 Nov 2010 Birt Hogg Dubè Syndrome, the pulmonologist point of view Giornata di Informazione sulla sindrome di Birt Hogg Dubè. Az Osp S Croce Carle, Cuneo, ITALY
7. 1 Dec 2010 Clinical case of Sarcoidosis Le Malattie Rare del Polmone. Modena Univeristy, Modena, Forlì ITALY
8. 4-6 April 2011 Practical approaches to Idiopathic Pulmonary Fibrosis ERS scientific group on DPLD post graduate course, PneumoTrieste, Trieste, ITALY
9. 30 Nov-3 Dec 2011 Evoluzione e storia naturale delle pneumopatie interstiziali - IPF e cancro XII National Congress UIP, Bologna, ITALY
10. 26-28 March, 2012 Clinical differential aspects of IPF.
11. 12-14 April, 2012 ERS course at PneumoTrieste Annual Meeting, Trieste, ITALY Lectures: A) Fibrosi Polmonare Idiopatica : la clinica. B) Le pneumopatie infiltrative diffuse: nuove acquisizioni. Villanovaforru, Cagliari.
12. 3-5 May 2012 Le PID con pattern reticolare III post graduate course: le PID conoscere per riconoscere. Gubbio, Italy.
13. 26-27 Oct, 2012 Pirfenidone Named Patient Program. AIR Meeting Italia. Rome, Italy.
14. 8-10 April, 2013 Different clinical profiles of IPF. ERS course at PneumoTrieste Annual Meeting, Trieste, ITALY
15. 17 April, 2013 La clinica delle interstiziopatie polmonari. Corso di patologia pleuro-polmonare. Dipartimento Anatomia Patologica, Università degli Studi di Verona, Italy.
16. 27 April, 2013 Criobiopsia Sorrento Breathing, Sorrento, Italy.
17. 7-9 Maggio, 2013 La IPF: la clinica Pneumopatie infiltrative diffuse, asma e BPCO. Villanovaforru, Cagliari, ITALY
18. 28-29 June, 2013 L'esperienza NPP in Italia: cosa abbiamo imparato. AIR MEETING ITALIA 2013. Milano, Italy.
19. 7-9 April 2014 Idiopathic Pulmonary Fibrosis, clinical aspects
20. ERS scientific group on DPLD post graduate course, PneumoTrieste, Trieste, ITALY
21. 7-8 June 2014 Novel Therapies for IPF. Asthma, IPF and other ILDs. Assisi, ITALY
22. 27-28 June, 2014 IPF, mystery case AIR MEETING ITALIA 2014. Rome, Italy.
23. 1-3 oct, 2014 Update on ILD. FIP, National Pulmonology Congress, Genova, Italy.
24. 8-11 Sept ,2014 La clinica delle interstiziopatie polmonari. PneumoCampania 2014 - 7^a edizione Vietri sul Mare, Italy.
25. 23-25 Oct 2014 Clinical cases on ILDs III post graduate course: le PID conoscere per riconoscere. Gubbio, Italy.

26. 28-29 Nov, 2014 “Clinica e terapia della IPF;” Updates in Pneumologia, Cosenza, Italy
27. 5-6 Nov, 2014 Staging e FU della IPF, IPF workshop, Palermo, Italy
28. 7-8 Nov, 2014 “IPF aspetti clinici e terapeutici”; Convegno interregionale ASPAM Terni, IT
29. 14-15 Nov, 2014 “Diagnosi della IPF con tecniche invasive”; AIPO Toscana, Massa Carrara, IT
30. 5-6 Feb 2015 “Le metodiche invasive”; Orizzonti in pneumologia, Verona, IT
31. 13-15 April 2015 “PPFE, NSIP, HP”; Pneumotrieste 2015, Trieste, IT
32. 9 May, 2015 “Grande fornitore di UIP”; 20anni di trapianto, Padova, IT
33. 29-30 May, 2015 “DIAGNOSIS OF PULMONARY FIBROSIS, WHAT’S NEW?”; he Missing Links, Roma, IT
34. 25-26 June, 2015 “End point dei trial clinici nella IPF, cosa migliorare”; Air meeting Italia, Roma, IT
35. 2 Oct, 2015 “Clinical case”; LA DIAGNOSI MULTIDISCIPLINARE E LE SCELTE TERAPEUTICHE DELLE PID e IPF; Firenze, IT
36. 9-10 Oct, “IPF:an heterogeneous entity”; AIPO Lazio, Nemi, Roma, IT
37. 16-17 Oct, “IPF profile clinic e stadiazione”; IPF next generation, Matera, IT
38. 19 Oct, 2015 “IPF”; Confidence, Trieste, IT
39. 6 Nov, 2015 "I misteri delle malattie dell'interstizio polmonare ed i segreti del ventricolo destro" San Daniele del Friuli, Udine, IT
40. 11-15 Nov, 2015 AIPO, Annual National Congress. Naples, IT:
41. 12-14 Nov AIPO National Annual Congress. Naples, IT, “Highlights dalle recenti linee guida/raccomandazioni nazionali ed internazionali 13 Nov, “Common Variable Immunodeficiency” 14 Nov, “IPF treatment”
42. 11, Dec 2015 “Biopsia per via endoscopica o chirurgica?” Pneumoroama , Roma, IT
43. 12, Dec 2015 “UIP il punto sul Pirfenidone e le nuove terapie” Updates in Pneumologia. Mendicino, CS, IT
44. 10 April, 2015 PIDAIPO giovani, Bologna, IT
45. 5-6 June, 2015 “L’imaging come guida alle procedure endoscopiche”; AIPO Pneumo Interventistica; Bologna, IT
46. 13 June, 2015 “New mini invasive diagnostic techniques”; MAR, Modena, IT
47. 21—22 Jan, 2016 “La fibrosi polmonare idiopatica: patogenesi e terapia” Bari Pneumologica. Bari, IT
48. 18-20 Feb, 2016 “Lo Pneumologo: il nuovo documento AIPO-SIMeR” Il futuro della pneumologia... la pneumologia del future. Lecce, IT
49. 12-13 April, 2016 “New frontiers. Early IPF” ERS course DPLD. Respiro Trieste. Trieste, I
50. 14-15 April, 2016 “La terapia medica della fibrosi polmonare idiopatica: passato, presente e futuro” Aggiornamento sulle patologie polmonari. Taranto, IT
51. 16 April, 2016 “Biomarkers: quale utilità ai fini diagnostici, prognostici e di risposta alle terapie” Innovazione ed organizzazione in pneumologia. Matera, IT
52. 20 April, 2016 “Attualità in tema di IPF” Congresso sez regione AIPO ER. Baggiovara, Modena, IT
53. 28-30 April, 2016 “Le Infezioni disseminate” Le pneumopatie interstiziali diffuse. Gubbio, IT
54. 6 May, 2016 “Dagli elementi anatomo-patologici all’Imaging. Quali certezze per il clinico?” Col fiato corto 6. Palermo, IT
55. 27 May, 2016 “Fibrosi e granulomatosi polmonare da droghe” 11° Pneumosalento. Lecce, IT
56. 17-18 June, 2016 “Terapia dell’IPF” La criobiopsia nella patologia parenchimale diffusa. Genova, I
57. 23-25 June, 2016 “I marcatori di patologia nell’IPF: molecolari, funzionali, clinico-radiologici” AIR Meeting National. Baveno, IT
58. 7-8 Oct, 2016 “La gestione diagnostica dei casi “difficili” e il ricorso alla biopsia: quando è necessaria una diagnosi istologica e come eseguirla”. Le pneumopatie infiltrative diffuse. Chieti, IT

59. 8 Nov, 2016 “CriobiopsiaLa patologia toracica di interesse chirurgico e medico: le convergenze parallele. Verona, IT
60. 11 Nov, 2016 “Nuove linee guida nazionali ed internazionali della IPF: similitudini differenze”AIPO regione Marche. Civitanova Marche, IT
61. 15-17 Dec, 2016 “Markers molecolari della IPF e dei suoi mimickers”Pneumoroma. Roma, IT
62. 2-3 Jan, 2017“La terapia della NSIP Orizzonti in Pneumologia. Verona, I
63. 31 March-1 April, 2017 Il trattamento «ritardato» nell’IPF è ancora accettabile? Oxford DebateAIR Meeting Italy, Bologna, IT
64. 3-5 April, 2017 “ILA prevalence and clinical relevance”ERS course DPLD. Respiro Trieste. Trieste, IT
65. 10 e 31 May, 2017speaker and tutor Sliding Doors course for pulmonologists, Padova, IT
66. 26-27 May, 2017 Speaker: “La criobiopsia nella diagnosi dell S.S.D.PNEUMOLOGIA”
Settore Aggiornamento e Formazione INTERNATIONAL CONGRESS, Courmayeur, Aosta IT
67. 10-13 June,2017 Speaker: “PID Acute” 12 JuneChair: “ Granulomatosi polmonari” 13 June AIPO, National Congress of Italian Pulmonology, Bologna, I
68. 16-17 June, 2017 Speaker: “Pattern fibrosante: quando è IPF”, and clinical cases presentationFibrosing lung diseases a MD approach, Ancona , IT
69. 4- Nov, 2017 Course: La fibrosi polmonare idiopatica, Brindisi , IT
Lectures:“Meccanismipatogenetici e correlazioni radiologiche e patologiche” “Il profilo della early IPF”
70. 30 Aprile, 2017 “PID: approccio diagnosticoCourse: XIV corso teorico-pratico Pneumologia Interventistica, Parma, IT
71. 1-2 Feb, 2018 Lecture: “IPF e tumore polmonare: modalità di gestione dell’esperienza clinica” IPF Connect, Ancona, IT
72. 21 Febbraio 2018 L’esperienza del centro di Forlì Confronto delle esperienze real life, Torino,IT
73. 9 March, 2018 Lectures: “Esperienza del centro di Forlì” Gli esperti a confronto, Padua , IT
74. 3-5 May, 2018Lectures: “Early IPF, a progressive disease to treat” The pathogenesis of COPD and IPF , Florence, IT
75. 5-26 May, 2018 Lectures: “Pattern fibrosante quando è IPF”“La terapia della IPF” Fibrosing Lung Diseases, Ancona , IT
76. 3-5 May, 2018Lectures: “Early IPF, a progressive disease to treat” The pathogenesis of COPD and IPF , Florence, IT
77. 22-23 June, 2018 Lecture: “I punti fermi dello pneumologo, diagnostica e decisione terapeutica” AIR meeting Italia, Baveno, IT
78. 22 Sept, 2018Lecture “IPF”Giornata mondiale della IPF, Pistoia, IT
79. 1 October, 2018 Lecture: “Treatment of IPF” and “Clinical cases”Transbronchial Cryobiopsy a course for pathologists, Milan, IT
80. 4 October, 2018 lecture: “Comorbidità e IPF”La gestione multidisciplinare delle PID, Foggia,4 Ottobre 2018
81. 21 Dec, 2018 Lecture: “pattern fibrosante” e “Terapia della IPF, Bologna IT
82. 13-15 Dec, 2016 “Terapia delle interstiziopatie quasi IPF”Pneumoroma. Roma, IT
83. 18 Gennaio 2018 L’esperienza del centro di ForlìConfronto delle esperienze real life, Torino,IT
84. 13-15 Febbraio, 2019 “Terapia della IPF” EURX 6° Incontro, Bolzano, IT
85. 1-3 April,2019 “Mystery case”PneumoTrieste, Trieste, IT
86. 14-15 June, 2019. AIR Italy national meeting, Turin, IT. Lecture: IPF and lung cancer
87. 6-7 Sept, 2019. World Scleroderma Lung Foundation, ILD-SSc master class. Lecture: Is lung biopsy necessary today in ILD?
88. 13-16 Nov, 2019. AIPO National congress. Lectures:
a. TBLC: validation for diagnosis and prognosis of iLDs
b. Linee guida: stesura e significato
89. 13 Dec, 2019. PneumoRoma. Lecture: IPF in 2019.

90. 18-19 Oct, 2019, Naples, IT. ILD Vernissage. Nuove metodologie diagnostiche in ILD
91. 24-25 Jan, 2020. Bologna, IT. Pneumopatie diffuse fibrosanti e non. Lecture: Prosepttive terapeutiche PID Fibrosanti.
92. SIP and AIPO, Italian IPF Guidelines National Event (multiple events):
 - a. Lecture: Invasive diagnosis of IPF. 31 Jan 2020, Milan IT.
 - b. Lecture: IPF diagnosi differenziale e inquadramento. 30 Sept, 2020 – on line
 - c. Chair and speaker, AIPO Toscana. IPF diagnosis. 12 Nov, 2020.
93. 7 Feb, 2020. Turin, IT. Terapie IPF. Lectures: 1) “News ATS-ERS”, 2) Early IPF treatment.
94. 14 Feb, 2020. Turin, IT. Role of awake biopsy in PID. Lecture: Awake biopsy and cryobiopsy comparison.
95. 18 June, 2020. Reggio Emilia web course: ipotesi patogenetiche di danno sub-acuto polmonare in pazienti post COVID19
96. 18 Sept 2020, Transbronchial lung cryobiopsy ERS-AIPO course. Web. Lecture: TBLC diagnostic and prognostic impact.
97. 29-30 Sept, 2020. IPF and friends, AIPO on-line event. Lecture title: “IPF: Terapia, an Update”.
98. 5-7 Oct, 2020. Respiro Trieste (on-line). Lectures: “Current and future treatment SSc-ILD”; “Cryobiopsy pro”.
99. 7 Oct, 2020. OMAR, on-line event. Lecture: Autoimmunity, Scleroderma and lung involvement.
100. 23 Oct, 2020. ERN lung, Pavia (on-line). Lecture: “S interstiziale post COVID-19: nuova o vecchia ILD?”.
101. 4-5 May, 2021. PF-ILDs. SIP course (web). Lecture: “Lung biopsy in ILDs”.
102. 20-22 Sept 2021. ERS course on ILD, respiroTrieste (web). Lecture: “Bronchiolitis, an update.”
103. 6-9 Oct 2021. Soc Italiana Radiologia Medica, National Congress, Parma (web). Chair IPF symposium sponsored BI.
104. 6-8 Nov 2021. AIPO-ITS national congress. 1. Oral presentation: 4 Nov 2021 (web): “EBUS and EUS”. 2 Oral presentation 15 Nov 2021 (web): “Fibrotic ILDs”. 3. Oral presentation 24 Nov 2021 (web): “COVID-19 in IPF”. 3. Live session, 6 Nov 2021 (live): Bronchoscopy hands on.
105. 17 Dec 2021. Pneumoroma, Roma. Oral presentation: “post COVID-ILD”.
106. 21-22 April, 2022. PF-ILD academy. Catania, IT. Clinical cases presentation.
107. 29 April 2022. Interventional Pulmonology body lab experience. Oral presentation: ILD: indicazioni all’accertamento biotico.
108. 28 May 2022. Pneumomedicina 2022, Milano. Lecture: ILA una nuova entità?
109. 14 Giugno 2022. Pneumotrieste. Trieste, IT. Lecture: Technique and safety of pulmonary cryobiopsy.
110. 1 Oct 2022. Congresso di Pneumologia Interventistica. Milano, IT (web). Lecture: La diagnosi con criobiopsia.
111. 6 November 2022. SIP national congress. Lecture: ILA cosa sono e cosa fare.
112. 25 November 2022. SIR national congress. Lecture: SSc and lung fibrosis.
113. 23-24 February 2023. La Fibrosi polm progressiva. Roma, IT. Lecture: Criobiopsia chi come quando.
114. 8-11 June 2023. AIPO national congress. Bari, IT. Lectures: 1. Peripheral lung nodules; 2. ILA.
115. 23-24 June 2023. ILD updates. Ancona, IT. Lecture: Early diagnosis.
116. 1 June 2023. AMAR-ODV congress (virtual). Lecture: Sarcoidosis.
117. 5-6 October 2023. TBLC Ravenna, Italy. Lectures: The diagnostic work-up for ILDs: a logic approach.
118. 26-27 October 2023. PID, Forlì, IT. Clinical cases discussion and Lecture: ILDs: Progressive fibrosing phenotype.
119. 11-13 December 2023. Mediastinal tracheo-bronchial cryobiopsy (Cryo-EBUS). Florence University, Florence, IT. Chair of the course. Live endoscopy session. Lecture: Cryobiopsy.

120. 15 December 2023. Corso alta specializzazione in bpcO e malattie rare del polmone Interstiziopatie polmonari fibrosanti progressive. Torino, IT. Lecture: PID fibrosanti progressive.
121. 27 January 2023. La multidisciplinarietà nelle patologie polmonari “una opportunità per tutti”. Rovigo, IT. Lecture: La diagnosi endoscopica delle PID.
122. 9-10 February 2024. Lung 2024 – le complessità nelle patologie respiratorie. Rende, CS, IT. Gestione e aspetti multidisciplinari nei pazienti con Fibrosi polmonare alla luce delle nuove linee guida.
123. 8 March 2024. Tissue is the issue. L’evoluzione dell’approccio diagnostico multidisciplinare nel tumore del polmone. Padova, IT. Lecture: Stadiazione del tumore polmonare.
124. 21-22 March 2024. IPF and friends. Forlì, IT. Lecture: Polmonite da ipersensibilità.
125. 6-8 May 2024. PneumoTrieste. Lectures: 1) Interstitial Lung Abnormalities (ILA): an impending disease, almost a disease or nothing?; 2) The combination of cryobiopsy and ultraThin bronchoscopy for the peripheral lung nodule
126. 30-31 May 2024. Pneumomedicina 2024, Milan, IT. Lectures: 1) Fibrosi polmonare in corso di IPAF: trattare con antifibrotici?
127. 12-14 June 2024. Firenze, IT. Resp scientifico della I ed del Corso Mayo Clinic Pulmonary Case studies.
128. 21 June 2024. Roma, IT. EUSTAR EULAR. Il polmone nella SSc, nuovi orizzonti. Lecture: Il trattamento antifibrotico della fibrosi polmonare idiopatica e malattia interstiziale del polmone
129. 27-28 June 2024. Turin, IT. SIAPEC. Master di patologia Toracica. Lecture: Ultime novità nelle fibrosi polmonari. Il punto di vista dello pneumologo.
130. 26-27 September 2024. Genova, IT. IP lung forum. Lecture: Italian EBUS guidelines
131. 3-4 October 2024. Ravenna, IT. TBLC. Lecture: ILA: what it is.
132. 16-18 November 2024. Milan, IT. SIP national congress. Lecture: La criobiopsia nelle malattie interstiziali polmonari
133. 6-7 dicembre 2025. Roma, IT. PneumoRoma. Lecture: Nuove tecniche endoscopiche.
134. 14 March 2025. On line. Forlì. IPF and friends. Lecture: ILA cosa fare.
135. 25 March 2025. Meldola, IT. Lung cancer, where are we. Lecture: cryoBx a new tool for NSCLC.
136. 12-14 May 2025. Trieste, IT. PneumoTrieste. Lecture: La pneumopatia iatrogena cui ci si pensa meno dell’ amiodarone
137. 12-13 June 2025. Ancona, IT. Resp Scientifico II edition of the Mayo Clinic and Brompton’s Hospital Pulmonary Case Studies.

- **Eventi locali, Emilia-Romagna:**

1. 15-16 Sept 2006 Clinical Case - Lymphoproliferative Lung Disorders Ematologo e Pneumologo Congress – GB Morgagni Hospital, Forlì, ITALY
2. 26-27 Jun 2007 Lung Lymphoproliferative Disorders Pneumopatie infettive e pseudoinfettive. GB Morgagni Hospital, Forlì Giugno ITALY
3. 13 Nov 2007 Lymphoproliferative disorders: the role of pulmonology Stage in Ematologia: linfomi polmonari, i progressi della conoscenza. Università Studi di Bologna, Bologna ITALY
4. 27-28 Nov 2007 Idiopathic Pulmonary Fibrosis Corso teorico-pratico. Interstiziopatie polmonari. GB Morgagni Hospital, Forlì ITALY
5. 4-8 Feb 2008 Idiopathic Pulmonary Fibrosis Corso residenziale. Interstiziopatie polmonari. GB Morgagni Hospital, Forlì ITALY

6. 26-27 Jun 2008 Lung Lymphoproliferative Disorders Pneumopatie infettive e pseudoinfettive. GB Morgagni Hospital, Forlì Giugno ITALY
7. 15-19 Sep 2008 Idiopathic Pulmonary Fibrosis Corso teorico-pratico. Interstiziopatie polmonari. GB Morgagni Hospital, Forlì ITAL
8. 25-27 Jan 2010 Idiopathic Pulmonary Fibrosis Corso teorico-pratico. Interstiziopatie polmonari. GB Morgagni Hospital, Forlì ITAL
9. 18 May 2010 Oxygen therapy in IPF Corso teorico-pratico. Hospice, Forlimpopoli, ITALY
10. 14-16 June 2010 Idiopathic Pulmonary Fibrosis Corso teorico-pratico. Interstiziopatie polmonari. GB Morgagni Hospital, Forlì ITALY
11. 13-15 Dec 2010 Idiopathic Pulmonary Fibrosis, Corso teorico-pratico. Interstiziopatie polmonari. GB Morgagni Hospital, Forlì ITALY
12. 16 Dec 2010 Therapeutic approaches of Idiopathic Pulmonary Fibrosis RIPID workshop. Fibrosi ed ipertensione polmonare. GB Morgagni Hospital, Forlì ITALY
13. 28-29 Feb 2012 1) La clinica della IPF, 2 La terapia della IPF. Corso: La Fibrosi Polmonare Idiopatica. GB Morgagni Hospital, Forlì ITAL
14. 5-7 March 2012 1) La Fibrosi polmonare Idiopatica 3) Le vasculiti Corso: Le Pneumopatie infiltrative diffuse. GB Morgagni Hospital, Forlì ITALY
15. 30 October, 2012 Corso : La Fibrosi Polmonare. GB Morgagni Hospital, Forlì ITALY
16. 19-20 Feb, 2013 1 La clinica della IPF 2 La terapia della IPF Corso: La Fibrosi Polmonare Idiopatica. GB Morgagni Hospital, Forlì ITAL
17. 20-22 March, 2013 La Fibrosi polmonare Idiopatica Corso: Le Pneumopatie infiltrative diffuse. GB Morgagni Hospital, Forlì ITALY
18. 10-12 April, 2013 1) La clinica della IPF La terapia della IP Corso: le Pneumopatie Infiltrative Diffuse. GB Morgagni Hospital, Forlì ITAL
19. 9 Dec 2013 La Fibrosi polmonare Idiopatica Corso Speed-it. GB Morgagni Hospital, Forlì ITALY
20. 24 Jan 2014 Diagnosis and treatment of DPLDs. Corso Insuff Respiratoria. Museo Internazionale delle ceramiche, Faenza, ITALY.
21. 27-28 March 2014 IPF, Clinical Cases presentation. CSI in IPF, Cube Hotel, Ravenna, ITALY.
22. 3-4 Feb, 2015 Clinica della IP Corso IPF, Forlì, IT
23. 3-5 March, 2015 Clinica della IPF; Corso PID, Forlì, IT
24. 15-17 June, 2015 "IPF clinica"; Corso AIPO PID, Forlì, IT
25. 8-9 Sept, 2015 "A future view on ILD" and "The MDD in ILD diagnosis"; Cryobiopsy meeting second ed., Ravenna, IT
26. 18 Sept, 2015 "Clinical case"; Convegno nazionale SIRM, Parma, IT
27. 9-11 Feb, 2016 "Clinica della IPF e dintorni" Fibrosi Polmonare Idiopatica. Forlì, FC, IT
28. 7-9 June, 2016 "Fibrosi polmonare idiopatica: clinica" e "Procedure diagnostiche invasive" Corso Pneumopatie infiltrative diffuse. GB Morgagni H, Forlì, FC, IT
29. 3-4 and 24-25 May, 2016 In Hospital Meeting: IPF Excellence. Forlì IT 3 May, "Il profilo clinico della IPF" 4 May "La terapia della IPF" 5 May "La criobiopsia polmonare"
30. 28-19 Oct, 2016 "Treatment of IPF : an update" TBLC in DPLD. Endorsed by ERS. Ravenna,
31. 21 Oct, 2016 Meet the Expert in IPF. Forlì, FC, IT "Opzioni terapeutiche nel trattamento dell'IPF" "Casi clinici multidisciplinari: dalla diagnosi alla cura del paziente con IPF – Esperienze a confronto" "Stars e Black Holes: successi e problematiche irrisolte dei Centri di riferimento. Modelli e risultati organizzativi dei Centri e problematiche gestionali"
32. 19 Oct, 2016 "Ottimizzare la gestione del paziente con BPCO" ECM 38-164989. Forlì, Italy
33. 3 Nov, 2016 "La visione del clinico" "FARMACISTI A CONFRONTO: APPROPRIATEZZA TERAPEUTICA, BUDGET DI SPESA E GESTIONE DELLE GARE" Rimini, I

34. 13-14 Dec, 2016 “La diagnosi differenziale” LA CONDIVISIONE DELLA PRATICA CLINICA NELLA FIBROSI POLMONARE IDIOPATICA. 9 national centres web-connected. Forlì, IT.
35. 14-16 Feb, 2017 “Profili clinici IPF e quasi IPF” and “Early IPF and IPF friends perchè e quando trattare” Course: IPF and friends. Forlì, I
36. 8-9 Maggio, 2017 Lectures: “Opzioni terapeutiche” “Aspetti organizzativi nella gestione del paziente” Tavola rotonda Course: Clinical management of IPF, Ravenna, IT
37. 20-21 June, 2017 Lecture: “IPF” and Chair of the session “Patologia sistematica I” Course: Pneumopatie infiltrative diffuse, Forlì, IT
38. 24 Sept, 2017 Lecture: “ILDs, la gestione del paziente in Italia: differenze tra teoria e pratica clinica” Course: Respirare e Comunicare, Forlì, IT
39. 9-10 Nov, 2017 Lecture: “Novità dai congressi internazionali: aspetti clinici” Course: IPF in Practice personalizzare l’algoritmo terapeutico, Ravenna, IT
40. 22 febbraio, 2018 “Terapia dell’IPF et similia IPF and Friends, Forlì, IT
41. 15-16 March, 2018 Lectures: “La gestione del paziente acuto” “La terapia di IPF e quasi IPF” “IPF e quasi IPF” Course: Respirare e comunicare, Forlì, IT
42. 26 e 28 Giugno 2018 Lecture: “Patogenesi del tumore polmonare similitudini con il cancro” Pneumopatie Infiltrative Diffuse, Forlì, IT
43. 19-20 Febbr, 2019 “Profilo clinic della IPF” IPF and Friends, Forlì, IT
44. 19-20 Feb, 2019 IPF and friends. AIPO course, Forlì, I
45. 25-27 June, 2019, PID course, Forlì, IT
46. 27 Feb, 27 March, 17 April, 11+25 Oct, 29 Nov, 2019-IPF challenging clinical cases. Forlì IT
47. 24 January, 2020. PID and MDT. Lecture. “treatment of progressive fibrosing ILDs”.
48. 26-27 Nov, 2020 PID. AIPO course, Forlì (web). Lecture “IPF treatment update”
49. 26 Nov 2021. Società Italiana di Reumatologia National Congress, Rimini (live). BI sponsored symposium, oral presentation: “When PF is progressive”.
50. 10-11 June 2021. IPF and friends, Forlì (web). Lecture: “IPF an update”.
51. 7-8 April, 2022. IPF and Friends, Forlì. Lectures: Progressive fibrotic ILD.
52. 21-22 oct 2022. PID Forlì, IT. Lecture: progressive fibrotic phenotype.
53. 20-21 April 2023. IPF and friends. Forlì, IT. Polmoniti da ipersensibilità.
- 54. 26 June 2023. Meet the Professor Naftali Kaminski, Yale Univ USA. Florence, IT. Chair of the event.**

- **Eventi locali, 2020-currently Florence and Tuscany:**

1. 23 Oct, 2020. Florence, IT (on-line). Unmet needs in thoracic oncology. Lecture: “lung cancer and ILDs”.
2. 24 May, 2021. Florence. PID, Lecture on cryobiopsy in ILDs.
3. 7 June 2021. Florence, IT. L’importanza della multidisciplinarietà’ Lecture on cryobiopsy in ILDs.
4. 24-25 Sept 2021. AIPO-ITS Tuscany regional congress. Lecture: “Innovative biopsy methods in ILDs”.
5. 7 Giugno 2022. Fibrosi polmonare idiopatica o secondaria. Florence, IT. Lecture: ERN lung for rare respiratory diseases.
6. 6 e 11 Luglio 2022. Crio a tutto tondo (virtual only). **Event chair.**
7. 9 Sept 2022. Meet the Expert, Maurizio Chiocciolini, Yale University USA. Florence, IT. **Event chair.**
8. 24 Nov 2022. Rete ILD (virtual only). Lecture: ILD related to CTD when to treat?
9. 10 May 2023. Corso Universitario di perfezionamento in broncoscopia rigida. Lettura: tecniche di criodebulking e crioablazione.
10. 16 June 2023. FP diagnosi e terapia. Florence, IT (web). Lecture: UIP in AR.

11. 28 October 2023, La trasversalità della ricerca in pneumologia: la rete delle Università in Toscana tra presente e futuro. Pisa, IT. Lecture: Pneumologia interventistica formazione e ricerca per lo pneumologo.
12. 18 Novembre 2023. PF-ILD expert sharing. Firenze, IT. Lecture: Il ruolo della criobiopsia nella diagnosi di ILDs.
13. 20 december 2023. Seminario Università degli Studi di Siena, IT. Lettura: "La criobiopsia per la diagnosi delle patologie toraciche"
14. 3 february 2024. Montespertoli, Fi, IT. Corso avanzato per MMG. Lecture: Metodiche endoscopiche innovative di diagnosi e terapia.
15. 9-11 April 2024, Firenze, IT. Corso di broncosocopia rigida. Lecture: Gli strumenti di ablazione. La criobiopsia per il trattamento e la diagnosi.

Progetti di ricerca

Titolare di Grant per la Ricerca

12/2017, HISTORICAL EYE IPF. Investigator Initiated Study (IIS) funded by Roche and AMMP (Ass Morgagni Mal Polmonari). Title: 15 years of real life data to study the shifting mortality scenario of IPF Retrospective study evaluating factors that have impacted and changed IPF prognosis. Approvazione N 8571/2017. Published, PMID: 37332746.

Progetti di ricerca sponsorizzati o finanziati.

○ Finanziati dall'Unione Europea

1. 2020-2023 Dragon consortium: **Sub-Investigator** with a study investigating the role of BAL and EBA in COVID-19 diagnosis. Title "Combined data analysis to define clusters of clinical presentation, severity and prognosis of COVID-19. " Approved Ethics Committee : Comitato Etico Regionale per la Sperimentazione Clinica della Regione Toscana Sezione: AREA VASTA CENTRO il 10/11/2020 Protocollo num 18099_bio). (ongoing)
2. 2010-2011, Sub-Investigator e **Membro del Comitato Scientifico**, RESOLVE, **funded by the European Commission** under FP7-HEALTH-F4-2008 Contract no. 202047. Clinical assessment of disease conditions and sequential analysis of biological data – to identify relevant molecular targets and separate them from those connected to regular organ repair. Studies relate to lung manifestations of progressive fibrotic disorders of the lung such as IPF and other ILDs.
3. 2011-2014 Acute Exacerbation of Idiopathic Pulmonary Fibrosis: Mechanism and Biomarkers. E-Rare2 JTC 2011- Funded by European Commission. The purpose of this prospective study is to investigate clinical and biomolecular aspects of acute exacerbation of IPF.

○ Trial clinici sponsorizzati

Principal investigator:

1. 2012-2018, **Principal Investigator**, INPULSIS-ON, NCT01619085. An open label extension trial of the long term safety of oral BIBF 1120 patients with Idiopathic Pulmonary Fibrosis (IPF) The primary objective of this study is to assess the long-term safety of BIBF 1120

- treatment in patients with Idiopathic Pulmonary Fibrosis who have completed one year treatment and the follow-up period in the phase III trials 1199.32.
2. 2013-2016, **Principal Investigator**, RAINER study, NCT01769196. A phase 2, randomized, double blind, Placebo – Controlled Multi centre study to assess the efficacy and safety of GS - 6624 .
 3. 2014-2016, **Principal Investigator e membro del comitato scientifico**, PASSPORT study, PIPF 025, NCT02699879. Safety profile of Esbriet® inpatients with IPF and to monitor for any unknown or potential risks of treatment with Esbriet. Post – Authorisation Safety Study of Esbriet (Pirfenidone), a prospective observational Registry to evaluate Long Term Safety in Real World Setting.
 4. 2014-2018, **Principal Investigator**, LEBRIKIZUMAB GB28547, NCT01872689 Efficacy and Safety of LEBRIKIZUMAB in patients with idiopathic pulmonary fibrosis A phase II, randomized, double – blind, placebo controlled to assess the efficacy and safety of Lebrikizumab in IPF.
 5. 2016-2018, **Principal Investigator**, FIBRONET, NCT02803580. "IPF Italian Observational Study (FIBRONET) " The primary objective of study is to evaluate the characteristics, management and clinical course of patients with IPF as treated under real-world in Italian Pulmonary Centres, in terms of symptoms, lung function and exercise tolerance during 12 months of observation. In particular, the study aims to provide information on disease characteristics and treatment modalities (at enrolment) and on disease progression. PROTOCOL NUMBER 1199.262.
 6. 2016-2018, **Principal Investigator**, INSTAGE BIBF 1199.36, NCT02802345. A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib co-administered with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment".
 7. 2016-2018, **Principal Investigator e membro del comitato scientifico**, ML39260 IRENE “An observational, retrospective, multicentre study to evaluate, the efficacy of Pirfenidone administered according to clinical practice to patients with idiopathic pulmonary fibrosis.
 8. 2016- 2019, **Principal Investigator**, MA29957, NCT02951429. The primary efficacy objective for this study is to evaluate the efficacy of adding sildenafil compared with placebo to pirfenidone treatment in patients with advanced IPF and intermediate or high probability of Group 3 PH. The primary efficacy endpoint will be evaluated based on a comparison of the proportion of patients showing disease progression over 52 weeks of treatment period
 9. 2017 - 2019 , **Principal Investigator**, PF-ILD trial, BIBF 1199.247. “A phase III trial on efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease” The aim of the current study is to investigate the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD). Based on its efficacy and safety in Idiopathic Pulmonary Fibrosis (IPF), it is anticipated that Nintedanib will be a new treatment option for patients with PF-ILD.
 10. 2017 - 2020, **Principal Investigator e Coordinatore Nazionale***, MA39189, NCT03099187 “A phase III Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease” The purpose of this study is to evaluate the efficacy and safety of pirfenidone in participants with fibrosing interstitial lung disease (ILD) who cannot be classified with moderate or high confidence into any other category of fibrosing ILD by multidisciplinary team (MDT) review ("unclassifiable" ILD).
 11. 2018- a tutt’oggi. **Principal Investigator**, CVAY736X2207, NCT03287414. Ianalumab (VAY736) is a human IgG1/κ monoclonal antibody (mAb) which targets B cells and their functions in B cell-mediated human diseases. The intended use for ianalumab is to provide an effective treatment for autoimmune diseases and B cell tumors.

12. 2018- a tutt'oggi. **Principal Investigator**, PF-ILD OPNE LABEL EXTENSION, BIBF 1199.248 An open-label extension trial of the long term safety of nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD).
13. 2018- a tutt'oggi. **Principal Investigator**, SPIRIT trial, NCT03573505. Biogen 203pf203 "Spirit" A Randomized, Iib phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis To evaluate the efficacy of BG00011, humanized monoclonal antibody against TGF-b compared with placebo in subjects with IPF.
14. 2019-2020, **Principal Investigator**, Galapagos GLPG1690-CL-303 Phase 3. EudraCT No.: 2018-001405-8 Sponsor: Galapagos
15. 2019-2020, **Principal Investigator**, Galecto Biotech, Galactic-1 Sponsor: Galecto Biotech. NCT03832946 . 2018-002664-73 (EudraCT Number)
16. 2021-2022, **Principal Investigator**, Safety of PRM-151 in IPF, phase III trial, Sponsor: Roche.
17. 2023-2024, **Principal Investigator**, Efficacy and Safety of IV Efstofitimod in patients with Pulmonary Sarcoidosis, Phase III, Sponsor: aTyr Pharma
18. 2023-2024, **Principal Investigator**, Efficacy and Safety of BI 1015550 in patients with IPF or PF-ILDs, Phase III, Sponsor: Boehringer Ingelheim
19. 2023-2024, **Principal Investigator**, Efficacy and Safety of Astegolimab in patients with COPD, Phase III, Sponsor: Roche
20. 2024-2025, **Principal Investigator**, Efficacy and safety of PLN-74809 (Bexotegast) for the treatment of IPF, Phase Iib/III Sponsor: Pliant Therapeutics
21. 2024-ongoing, **Principal Investigator**, Efficacy and Safety of Vixarelimab in patients with IPF and SSc-ILD, Phase II, Sponsor: Genentech
22. 2024-ongoing, **Principal Investigator**, Efficacy, Safety and Tolerability of Axatilimab in patients with IPF, Phase Iib, Sponsor: Syndax Pharmaceuticals
23. 2024-ongoing, **Principal Investigator**, An OPEN LABEL extension trial of the long-term safety and efficacy of BI 1015550 (Nerandomilast) taken orally in patients with IPF and PPF, Sponsor: Boehringer Ingelheim
24. 2024-ongoing, **Principal Investigator**, Efficacy, safety, and tolerability of BI1819479 in patients with IPF, Phase II, Sponsor: Boehringer Ingelheim
25. 2024-ongoing, **Principal Investigator**, Efficacy and safety of BI 1839100 in patients with IPF or PPF with clinically meaningful cough, Phase Iia/Iib, Sponsor: Boehringer Ingelheim
26. 2024-ongoing, **Principal Investigator**, Efficacy, Safety, and Tolerability of BMS-986278 (Admilparant) in patients with IPF, Phase III, Sponsor: Bristol Myers Squibb
27. 2024-ongoing, **Principal Investigator**, Efficacy, Safety, and Tolerability of BMS-986278 (Admilparant) in patients with PPF, Phase III, Sponsor: Bristol Myers Squibb
28. 2024-ongoing, **Principal Investigator**, The effects of ARO-MMP7 inhalation solution in patients with IPF, Phase Iia, Sponsor: Arrowhead Pharmaceuticals

Sub-Investigator:

1. 2005-2006, INSPIRE Trial, Phase III, NCT00075998
2. 2006-2009, CAPACITY trial, Phase III, NCT00287729
3. 2018-2020, SPIRIT TRIAL. Biogen 203pf203 "Spirit" A Randomized, Iib phase BG00011 in IPF. ClinicalTrials.gov Identifier: NCT03573505. EUDRACT 2017-003158-18. Biogen.
4. 2010, ARTEMIS IPF, Phase III, NCT00768300.
5. 2011-2012, INPUSLIS Trial, Phase III, NCT01335464.
6. 2011-2014, AE-IPF, Funded by European Commission, E-rare2, JTC 2011.

Study Coordinator:

1. 2008-2009, BUILD-3 trial, phase III, NCT00391443

Progetti di ricerca non sponsorizzati (selezione dei progetti più rilevanti dal 2010)

1. 2010, The diagnostic role of transbronchial biopsy in UIP Retrospective, blinded **Principal Investigator** Approved Ethics Committee : 22/06/2010 Nr. 1493/2010 (Published)
2. 2010, Pulmonary manifestations of Birt-Hogg-Dubè syndrome Retrospective Study **Principal Investigator** Approved Ethics Committee : 25/08/2010 Nr. 2613/2010 (Published)
3. 2010, Familial Interstitial Pneumonia Profile Retrospective Study **Principal Investigator** Approved Ethics Committee : 26/08/2010 Nr. 2611/2010 (Published, Feb 2014)
4. 2010, Anticoagulant therapy for Idiopathic Pulmonary Fibrosis Retrospective Study **Principal Investigator** Approved Ethics Committee : 29/10/2010 Nr. 3327/2010 (Published)
5. 2010, A simple, clinically relevant staging System for Idiopathic Pulmonary Fibrosis Retrospective Study Participating Centre Approved Ethics Committee : 08/04/2011 Nr. 1385/2011 (Published)
6. 2010, Is Medical Thoracoscopy indicated in the management of Multiloculated and Organized Thoracic Empyema? Retrospective Study Co – Investigator Approved Ethics Committee : 05/09/2011 Nr. 3386/2011 (Published):
7. 2012, The impact of lung cancer on survival of Idiopathic Pulmonary Fibrosis Retrospective Study Co – Investigator Approved Ethics Committee : 26/08/2012 Nr. 2611/2012 (Published)
8. 2012, The diagnostic role of Cryobiopsy in the multidisciplinary diagnosis of fibrotic interstitial lung diseases Retrospective Study in two steps. Phase one: safety and feasibility. Phase two: MDD. **Principal Investigator** Approved Ethics Committee : 27/06/2013 Nr. 3106/2012 (Phase I: published; Phase II :published)
9. 2014, Sleeping Disorders in IPF (DRS in IPF) Prospective **Co-PI** The purpose of this prospective study is to investigate clinical and physiopathological aspects of sleeping disorders of IPF. Approved by Ethics Committee, Published
10. 2015, Chest US post criobiopsy for the detection of PNX Prospective **Principal Investigator** The purpose is to investigate the role of transthoracic echography in detection of early postprocedural PNX Approved by EC, Published
11. 2018, CRYO III, Prognostic validation of cryobiopsy for the diagnosis of interstitial lung diseases Retrospective **Principal Investigator** Approved, 7732/2018 (Published)
12. 2019, Retrospective **Principal Investigator**, Clinical and prognostic significance of circulating autoantibodies in Idiopathic Pulmonary Fibrosis. Retrospective Monocentric Study. Approved by Ethics Committee n.2575 del 18.12.2019 prot IPAF di AUSL Romagna. (submitted)
13. 2020, Retrospective, **Principal Investigator**, CRYO IV, study on TBLC in ILDs entitled "Clinical and management implications of histologic informations provided by TBLC in ILDs". Substudy of CRYO III CEROM approval prot n 7732/2018, I.5 /247; CEROM approval for CRYO IV date 12/6/2020, numero 4795/2020/15/149 (presa d'atto). (submitted)
14. 2020, Retrospective, **Principal Investigator**, COVID-19 the BAL role in BAL in diagnosis of suspected COVID-19 with negative nasopharyngeal swabs, entitled: "Diagnostic accuracy of the clinical-HRCT diagnosis of COVID-19 in patients with negative nasopharyngeal swabs RT-PCR." Multicenter retrospective study. 2 Italian participating centres. Approved Ethics

- Committee : Comitato Etico Regionale per la Sperimentazione Clinica della Regione Toscana Sezione: AREA VASTA CENTRO il 30/06/2020 Protocollo num 17624_OSS). (ongoing)
15. 2021, Retrospective, multicentric international pilot study. **Principal Investigator**, “Superdimension and TBLC for the diagnosis of ILDs. Coordinating center: Aarhus Univertisty, Denmark. prot num 19916_oss; authorization Az Careggi, prot 17355 year 2021, 21-7-2021. (published)
 16. 09-2021-ongoing Membro del comitato scientifico (steering committee member) del Gruppo internazionale di ricerca sulle forme fibrosanti progressive, Delphi Survey (Published).
 17. 2020, Prospective, **Principal Investigator and National coordinator***, **PCOILS**: post COVID19 interstitial lung syndrome, radiologic pathologic correlations obtained by HRCT and TBLC. Prospective multicenter national study on cryobiopsy in post COVID fibrosis. 11 Italian participating centres. Approved Ethics Committee : Comitato Etico Regionale per la Sperimentazione Clinica della Regione Toscana Sezione: AREA VASTA CENTRO il 25/09/2020, prot 18098_oss. (ongoing)
 18. 2020-ongoing. BAL role for the diagnosis of suspected COVID-19 with negative nasopharyngeal swabs, entitled: “Diagnostic accuracy of the clinical-HRCT diagnosis of COVID-19 in patients with negative nasopharyngeal swabs RT-PCR.” **Multicenter restrospective** study. 2 Italian participating centres. Approved Ethics Committee : Comitato Etico Regionale per la Sperimentazione Clinica della Regione Toscana Sezione: AREA VASTA CENTRO il 30/06/2020 Protocollo num 17624_OSS). (ongoing)
 19. 2024- ongoing, **The crown** - Comparison of crown tip needle versus single bevel needle for guiding Transbronchial Mediastinal Cryobiopsy (TMC) in the Diagnosis of Mediastinal Lymph Nodes: Multicenter Prospective Interventional, randomized, open- label study on the safety and feasibility of the technique. **International, multicenter, prospective randomized trial. *International coordinating Centre**. Approved Ethics Committee: Comitato Etico Regionale per la Sperimentazione Clinica della Regione Toscana Sezione: AREA VASTA CENTRO il 15/10/2024, prot 25413
 20. 2024-ongoing, **The Thin-ICE protocol**: prospective, randomized and controlled multicenter trial evaluating the combination of ultra-thin bronchoscopy and cryobiopsy for the diagnosis of peripheral lung lesions. **International, multicenter, prospective randomized trial. *International coordinating Centre**. Approved Ethics Committee: Comitato Etico Regionale per la Sperimentazione Clinica della Regione Toscana Sezione: AREA VASTA CENTRO il 24/09/2024, prot 25414
 21. 2024-ongoing **The Retrospective Thin-ICE protocol**: monocentric, retrospective, observational pilot study evaluating the combination of ultra-thin bronchoscopy and cryobiopsy for the diagnosis of peripheral lung nodules. Approved Ethics Committee: Comitato Etico Regionale per la Sperimentazione Clinica della Regione Toscana Sezione: AREA VASTA CENTRO il 18/12/2024, prot 24567
 22. 2025-ongoing, **The Frozen Path**, Comparison of crown tip needle versus single bevel needle to guide Transbronchial Mediastinal Cryobiopsy (TMC) in the Diagnosis of Mediastinal Lymphadenopathies: Retrospective observational study on the feasibility and safety of the technique. Approved Ethics Committee: Comitato Etico Regionale per la Sperimentazione Clinica della Regione Toscana Sezione: AREA VASTA CENTRO il 18/02/2025, prot 26194

Pubblicazioni

Lavori originali

1. Antonello RM, Marangoni D, Ducci F, Barbiero A, Manciuilli T, Graziani L, Di Lauria N, Menicacci L, Paci L, Sordi B, Zammarchi L, Morettini A, **Tomassetti S**, Rossolini GM, Bartoloni A, Spinicci M. Antiviral combination regimens as rescue therapy in immunocompromised hosts with persistent COVID-19. *J Chemother.* 2025 Apr;37(2):130-134. doi: 10.1080/1120009X.2024.2367935. Epub 2024 Jun 14. PMID: 38873733
2. Nardi C, Magnini A, Rastrelli V, Zantonelli G, Calistri L, Lorini C, Luzzi V, Gori L, Ciani L, Morecchiato F, Simonetti V, Peired AJ, Landini N, Cavigli E, Yang G, Guiot J, **Tomassetti S**, Colagrande. Laboratory data and broncho-alveolar lavage on Covid-19 patients with no intensive care unit admission: Correlation with chest CT features and clinical outcomes. *S.Medicine (Baltimore).* 2024 Jul 19;103(29):e3902.
3. Pelagatti L, Montalbetti A, Viviani G, Ferretti A, Trigiani M, Corbetta L, **Tomassetti S**, Vanni S, Nazerian P. Fibrobronchoscopy versus laryngotracheal aspiration for bronchial toileting in patients with aspiration pneumonia in the emergency department. *FBS-ASaP prospective case-control study. Intern Emerg Med.* 2025 Jun 8. doi: 10.1007/s11739-025-04002-5. Online ahead of print.
4. Guiot J, Henket M, Gester F, André B, Ernst B, Frix AN, Smeets D, Van Eyndhoven S, Antoniou K, Conemans L, Gote-Schniering J, Slabbynck H, Kreuter M, Sellares J, Tomos I, Yang G, Ribbens C, Louis R, Cottin V, **Tomassetti S**, Smith V, Walsh SLF. Automated AI-based image analysis for quantification and prediction of interstitial lung disease in systemic sclerosis patients. *Respir Res.* 2025 Jan 24;26(1):39. doi: 10.1186/s12931-025-03117-9.
5. Wells AU, Walsh SLF, Adegunsoye A, Cottin V, Danoff SK, Devaraj A, Flaherty KR, George PM, Johansson KA, Kolb M, Kondoh Y, Nicholson AG, **Tomassetti S**, Volkmann ER, Brown Identification of progressive pulmonary fibrosis: consensus findings from a modified Delphi study. *Respir Res.* 2024 Dec 31;25(1):448. doi: 10.1186/s12931-024-03070. PMID: 39741294.
6. Polese B, Ernst M, Henket M, Ernst B, Winandy M, Njock MS, Blockx C, Kovacs S, Watar F, Peired AJ, **Tomassetti S**, Nardi C, Gofflot S, Rahmouni S, Schofield JP, Penrice-Randal R, Skipp PJ, Strazzeri F, Parkinson E, Darcis G, Misset B, Moutschen M, Louis R, Cavalier E, Guiot J. Circulating inflammatory cytokines predict severity disease in hospitalized COVID-19 patients: A prospective multicenter study of the European DRAGON consortium. *J Infect Public Health.* 2024 Dec;17(12):102589. doi: 10.1016/j.jiph.2024.102589. Epub 2024 Nov 6. PMID: 39547108.
7. Salvati L, Palterer B, Lazzeri E, Vivarelli E, Amendola M, Allinovi M, Caroti L, Mazzoni A, Lasagni L, Emmi G, Cavigli E, Del Carria M, Di Pietro L, Scavone M, Cammelli D, Lavorini F, **Tomassetti S**, Rosi E, Parronchi P. Presentation and progression of MPO-ANCA interstitial lung disease. *J Transl Autoimmun.* 2024 Jun;8:100235. PMID: 38445024; PMCID: PMC10912625.
8. Nardi C, Magnini A, Calistri L, Cavigli E, Peired AJ, Rastrelli V, Carlesi E, Zantonelli G, Smorchkova O, Cinci L, Orlandi M, Landini N, Berillo E, Lorini C, Mencarini J, Colao MG, Gori L, Luzzi V, Lazzeri C, Cipriani E, Bonizzoli M, Pieralli F, Nozzoli C, Morettini A, Lavorini F, Bartoloni A, Rossolini GM, Matucci-Cerinic M, **Tomassetti S**, Colagrande S. Doubts and concerns about COVID-19 uncertainties on imaging data, clinical score, and outcomes. *BMC Pulm Med.* 2023 Nov 25;23(1):472. PMID: 38084359.
9. **Tomassetti S**, Ravaglia C, Piciucchi S, Ryu J, Wells A, Donati L, Dubini A, Klersy C, Luzzi V, Gori L, Rosi E, Lavorini F, Poletti V. Historical eye on IPF: a cohort study redefining the mortality scenario. *Front Med (Lausanne).* 2023 Jun 2;10:1151922. doi: 10.3389/fmed.2023.1151922. PMID: 37332746; PMCID: PMC10273674.
10. **Tomassetti S**, Ravaglia C, Puglisi S, Wells AU, Ryu JH, Bosi M, Dubini A, Piciucchi S, Girelli F, Parronchi P, Lavorini F, Rosi E, Luzzi V, Cerinic MM, Poletti V. Clinical implications of interstitial pneumonia with autoimmune features diagnostic criteria in idiopathic pulmonary

- fibrosis: A case control study. **Front Med** (Lausanne). 2023 Feb 16;10:1087485. doi: 10.3389/fmed.2023.1087485. PMID: 36873871; PMCID: PMC9978138.
11. Bruinsma FJ, Dowty JG, Win AK, Goddard LC, Agrawal P, Attina' D, Bissada N, De Luise M, Eisen DB, Furuya M, Gasparre G, Genuardi M, Gerdes AM, Hansen TVO, Houweling AC, Johannesma PC, Lencastre A, Lim D, Lindor NM, Luzzi V, Lynch M, Maffé A, Menko FH, Michels G, Pulido JS, Ryu JH, Sattler EC, Steinlein OK, **Tomassetti S**, Tucker K, Turchetti D, van de Beek I, van Riel L, van Steensel M, Zenone T, Zompatori M, Walsh J, Bondavalli D, Maher ER, Winship IM; Genetic Susceptibility Working Group I-CONFIRM. Update of penetrance estimates in Birt-Hogg-Dubé syndrome. **J Med Genet**. 2023 Apr;60(4):317-326. doi: 10.1136/jmg-2022-109104. Epub 2023 Feb 27. PMID: 36849229.
 12. Peljto AL, Blumhagen RZ, Walts AD, Cardwell J, Powers J, Corte, TJ, Dickinson, JL, Glaspole I, Moodley YP, Vasakova MK, Bendstrup E, Davidsen JR, Borie R, Crestani B, Dieude P, Bonella F, Costabel U, Gudmundsson G, Donnelly, SC, Egan J, Henry MT, Keane MP, Kennedy MP, McCarthy C, McElroy AN, Olaniyi JA, O'Reilly KMA, Richeldi L, Leone PM, Poletti V, Puppò F, **Tomassetti S**, Luzzi V, Kokturk N, Mogulkoc N, Fiddler CA, Hirani N, Jenkins RG, Maher TM, Molyneaux PL, Parfrey H, Braybrooke R, Blackwell TS, Jackson PD, Nathan SD, Porteous MK, Brown KK, Christie JD, Collard HR, Eickelberg O, Foster EE, Gibson KF, Glassberg M, Kass, DJ, Kropski JA, Lederer D, Linderholm AL, Loyd J, Mathai SK, Montesi SB, Noth I, Oldham JM, Palmisciano AJ, Reichner CA, Rojas M, Roman J, Schluger N, Shea BS, Swigris JJ, Wolters PJ, Zhang Y, Prele CMA, Enghelmayer JI, Otaola M, Ryerson CJ, Salinas M, Sterclova M, Gebremariam TH, Myllärniemi M, Carbone RG, Furusawa H, Hirose M, Inoue Y, Miyazaki Y, Ohta K, Ohta S, Okamoto T, Kim DS, Pardo A, Selman M, Aranda AU, Park MS, Park JS, Song JW, Molina-Molina M, Planas-Cerezales L, Westergren-Thorsson G, Smith AV, Manichaikul AW, Kim JS, Rich SS, Oelsner EC, Barr RG, Rotter JI, Dupuis J, O'Connor G, Vasani RS, Cho MH, Silverman EK, Schwarz MI, Steele MP, Lee JS, Yang IV, Fingerlin TE, Schwartz DA. Idiopathic Pulmonary Fibrosis Is Associated with Common Genetic Variants and Limited Rare Variants. **Am J Respir Crit Care Med**. 2023 May 1;207(9):1194-1202. doi: 10.1164/rccm.202207-1331OC. PMID: 36602845; PMCID: PMC10161752.
 13. Spinicci M, Graziani L, Tilli M, Nkurunziza J, Vellere I, Borchini B, Mencarini J, Campolmi I, Gori L, Giovannoni L, Amato C, Livi L, Rasero L, Fattiroli F, Marcucci R, Giusti B, Olivetto I, **Tomassetti S**, Lavorini F, Maggi L, Annunziato F, Marchionni N, Zammarchi L, Bartoloni A. Infection with SARS-CoV-2 Variants Is Associated with Different Long COVID Phenotypes. **Viruses**. 2022 Oct 27;14(11):2367. doi: 10.3390/v14112367. PMID: 36366465; PMCID: PMC9698829.
 14. Karampitsakos T, Spagnolo P, Mogulkoc N, Wuyts WA, **Tomassetti S**, Bendstrup E, Molina-Molina M, Manali ED, Unat ÖS, Bonella F, Kahn N, Kolilekas L, Rosi E, Gori L, Ravaglia C, Poletti V, Daniil Z, Prior TS, Papanikolaou IC, Aso S, Tryfon S, Papakosta D, Tzilas V, Balestro E, Papisir S, Antoniou K, Bouros D, Wells A, Kreuter M, Tzouveleakis A. Lung cancer in patients with idiopathic pulmonary fibrosis: A retrospective multicentre study in Europe. **Respirology**. 2023 Jan;28(1):56-65. doi: 10.1111/resp.14363. Epub 2022 Sep 18. PMID: 36117239.
 15. Pan J, Hofmanninger J, Nenning KH, Prayer F, Röhrich S, Sverzellati N, Poletti V, **Tomassetti S**, Weber M, Prosch H, Langs G. Unsupervised machine learning identifies predictive progression markers of IPF. **Eur Radiol**. 2022 Feb;33(2):925-935. doi: 10.1007/s00330-022-09101-x. Epub 2022 Sep 6. PMID: 36066734; PMCID: PMC9889455.
 16. Ravaglia C, Doglioni C, Chilosi M, Piciocchi S, Dubini A, Rossi G, Pedica F, Puglisi S, Donati L, **Tomassetti S**, Poletti V. Clinical, radiological and pathological findings in patients with persistent lung disease following SARS-CoV-2 infection. **Eur Respir J**. 2022 Oct 6;60(4):2102411. doi: 10.1183/13993003.02411-2021. PMID: 35301248; PMCID: PMC8932282.

17. **Tomassetti S**, Sebastiani A, Caminati A, Oggionni T, Davì M, Ghirardini A, Martinoli MM. Raising awareness on physician-patient communication in IPF: an Italian multicenter study exploring the pulmonologist's perspective. *Sarcoidosis Vasc Diffuse Lung Dis.* 2021;38(3):e2021042. doi: 10.36141/svdl.v38i3.11400. Epub 2021 Sep 30. PMID: 34744429
18. **Tomassetti S**, Ravaglia C, Puglisi S, Ryu JH, Colby TV, Cavazza A, Wells AU, Pavone M, Vancheri C, Lavorini F, Matucci-Cerinic M, Rosi E, Luzzi V, Gori L, Rossi G, Donati L, Dubini A, Piciocchi S, Poletti V. Impact of Lung Biopsy Information on Treatment Strategy of Patients with Interstitial Lung Diseases. *Ann Am Thorac Soc.* 2021 Nov 5. doi: 10.1513/AnnalsATS.202104-466OC. Online ahead of print. PMID: 34739359
19. Orlandi M, Landini N, Sambataro G, Nardi C, Tofani L, Bruni C, Bellando-Randone S, Blagojevic J, Melchiorre D, Hughes M, Denton CP, Luppi F, Ruaro B, Della Casa F, Rossi FW, De Luca G, Campochiaro C, Spinicci M, Zammarchi L, **Tomassetti S**, Caminati A, Cavigli E, Albanesi M, Melchiorre F, Palmucci S, Vegni V, Guiducci S, Moggi-Pignone A, Allanore Y, Bartoloni A, Confalonieri M, Dagna L, De Cobelli F, De Paulis A, Harari S, Khanna D, Kuwana M, Taliani G, Lavorini F, Miele V, Morana G, Pesci A, Vancheri C, Colagrande S, Matucci-Cerinic M. THE ROLE OF CHEST CT IN DECIPHERING INTERSTITIAL LUNG INVOLVEMENT: SYSTEMIC SCLEROSIS VERSUS COVID-19. *Rheumatology (Oxford).* 2021 Jul 28;keab615. doi: 10.1093/rheumatology/keab615. Online ahead of print. PMID: 34320649
20. Nazerian P, Sacco RM, Solbiati M, Targetti E, Marta C, Blasi F, Casazza G, Colao MG, **Tomassetti S**, Grifoni S, Rossolini GM, Costantino G. Laryngotracheal aspiration test reduce the false negative rate in patients with suspected SARS-COV-2 pneumonia despite a negative nasopharyngeal swab. *Eur J Intern Med.* 2021 Jun 24;S0953-6205(21)00230-2. doi: 10.1016/j.ejim.2021.06.019. Online ahead of print. PMID: 34210553
21. Hunninghake GM, Goldin JG, Kadoch MA, Kropski JA, Rosas IO, Wells AU, Yadav R, Lazarus HM, Abtin FG, Corte TJ, de Andrade JA, Johannson KA, Kolb MR, Lynch DA, Oldham JM, Spagnolo P, Streck ME, **Tomassetti S**, Washko GR, White ES; ILA Study Group. Detection and Early Referral of Patients With Interstitial Lung Abnormalities: An Expert Survey Initiative. *Chest.* 2021 Jun 28;S0012-3692(21)01263-0. doi: 10.1016/j.chest.2021.06.035. Online ahead of print. PMID: 34197782
22. Smolinska A, Jessop DS, Pappan KL, De Saedeleer A, Kang A, Martin AL, Allsworth M, Tyson C, Bos MP, Clancy M, Morel M, Cooke T, Dymond T, Harris C, Galloway J, Bresser P, Dijkstra N, Jagesar V, Savelkoul PHM, Beuken EVH, Nix WHV, Louis R, Delvaux M, Calmes D, Ernst B, Pollini S, Peired A, Guiot J, **Tomassetti S**, Budding AE, McCaughan F, Marciniak SJ, van der Schee MP. The SARS-CoV-2 viral load in COVID-19 patients is lower on face mask filters than on nasopharyngeal swabs. *Sci Rep.* 2021 Jun 29;11(1):13476. doi: 10.1038/s41598-021-92665-3. PMID: 34188082
23. Bonifazi M, Mei F, Skrami E, Latini LL, Amico D, Balestro E, Bini F, Bonifazi F, Caminati A, Candoli P, Cinti S, Contucci S, Di Marco Berardino A, Harari S, Levi G, Lococo S, Menditto V, Marchetti G, Piciocchi S, Poletti V, Ravaglia C, Sietta M, Svegliati-Baroni G, **Tomassetti S**, Tamburrini M, Zanforlin A, Zuccon U, Zuccatosta L, Gasparini S, Carle F. Predictors of Worse Prognosis in Young and Middle-Aged Adults Hospitalized with COVID-19 Pneumonia: A Multi-Center Italian Study (COVID-UNDER50). *J Clin Med.* 2021 Mar 15;10(6):1218. doi: 10.3390/jcm10061218. PMID: 33804084
24. Cottin V, Richeldi L, Rosas I, Otaola M, Song JW, **Tomassetti S**, Wijsenbeek M, Schmitz M, Coeck C, Stowasser S, Schlenker-Herceg R, Kolb M; INBUILD Trial Investigators. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. *Respir Res.* 2021 Mar 16;22(1):84. doi: 10.1186/s12931-021-01668-1. PMID: 33726766
25. Funke-Chambour M, Albera C, Bendstrup E, Costabel U, Grutters JC, Harari S, Johannson KA, Kreuter M, Strambu I, Vancheri C, Varone F, Vitulo P, Wuyts WA, Martinez F, Raghu G; **Erice participants**. Suggestions for improving clinical utility of future guidelines for diagnosis

- and management of idiopathic pulmonary fibrosis: results of a Delphi survey. *Eur Respir J.* 2021 Apr 29;57(4):2004219. doi: 10.1183/13993003.04219-2020. Print 2021 Apr.PMID: 33419886
26. Lentz RJ, Colt H, Chen H, Cordovilla R, Popevic S, Tahura S, Candoli P, **Tomassetti S**, Meachery GJ, Cohen BP, Harris BD, Talbot TR, Maldonado F Assessing coronavirus disease 2019 (COVID-19) transmission to healthcare personnel: The global ACT-HCP case-control study. *Infect Control Hosp Epidemiol.* 2020 Sep 9:1-7. doi: 10.1017/ice.2020.455. Online ahead of print.PMID: 32900402.
 27. Hetzel J, Wells AU, Costabel U, Colby TV, Walsh SLF, Verschakelen J, Cavazza A, **Tomassetti S**, Ravaglia C, Böckeler M, Spengler W, Kreuter M, Eberhardt R, Darwiche K, Torrego A, Pajares V, Muche R, Musterle R, Horger M, Fend F, Warth A, Heußel CP, Piciocchi S, Dubini A, Theegarten D, Franquet T, Lerma E, Poletti V, Häntschel M. Transbronchial cryobiopsy increases diagnostic confidence in interstitial lung disease: a prospective multicenter trial. ***Eur Respir J.*** 2020 Aug 18:1901520. doi: 10.1183/13993003.01520-2019. Online ahead of print.PMID: 3281700.
 28. **Tomassetti S**, Ravaglia C, Wells AU, Cavazza A, Colby TV, Rossi G, Ley B, Ryu JH, Puglisi S, Arcadu A, Marchi M, Sultani F, Martinello S, Donati L, Gurioli C, Gurioli C, Tantalocco P, Hetzel J, Dubini A, Piciocchi S, Klersy C, Lavorini F, Poletti V. Prognostic value of transbronchial lung cryobiopsy for the multidisciplinary diagnosis of idiopathic pulmonary fibrosis: a retrospective validation study. ***Lancet Respir Med.*** 2020 Aug;8(8):786-794. doi: 10.1016/S2213-2600(20)30122-3.PMID: 32763205
 29. Sirol Aflah Syazatul S, Piciocchi S, **Tomassetti S**, Ravaglia C, Dubini A, Poletti V. Cryobiopsy in the diagnosis of bronchiolitis: a retrospective analysis of twenty-three consecutive patients. ***Sci Rep.*** 2020 Jul 2;10(1):10906. doi: 10.1038/s41598-020-67938-y.PMID: 32616807
 30. Bianchi R, Dubini A, Asioli S, Ravaglia C, **Tomassetti S**, Puglisi S, Piciocchi S, Gurioli C, Gurioli C, Fiocca R, Poletti V Transbronchial cryobiopsy: an effective tool in the diagnosis of lymphoproliferative disorders of the lung. ***ERJ Open Res.*** 2020 Jul 27;6(3):00260-2019. doi: 10.1183/23120541.00260-2019. eCollection 2020 Jul.PMID: 32743007
 31. Occhipinti M, Bruni C, Camiciottoli G, Bartolucci M, Bellando-Randone S, Bassetto A, Cuomo G, Giuggioli D, Ciardi G, Fabbrizzi A, **Tomassetti S**, Lavorini F, Pistolesi M, Colagrande S, Matucci-Cerinic M. Quantitative analysis of pulmonary vasculature in systemic sclerosis at spirometry-gated chest CT. ***Ann Rheum Dis.*** 2020 Sep;79(9):1210-1217. doi: 10.1136/annrheumdis-2020-217359. Epub 2020 Jun 30.PMID: 32606043
 32. Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M; **INBUILD trial investigators**. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. ***Lancet Respir Med.*** 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5.PMID: 32145830
 33. Barnes H, Morisset J, Molyneaux P, Westall G, Glaspole I, Collard HR; **CHP Exposure Assessment Collaborators**. A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. ***Chest.*** 2020 Jun;157(6):1506-1512. doi: 10.1016/j.chest.2019.12.018. Epub 2020 Jan 17.PMID: 31958445
 34. Salton F, Paola Confalonieri,¹,a G. Umberto Meduri,²,a Pierachille Santus,³ Sergio Harari,⁴ Raffaele Scala,⁵ Simone Lanini,⁶ Valentina Vertui,⁷ Tiberio Oggionni,⁷ Antonella Caminati,⁸ Vincenzo Patruno,⁹ Mario Tamburrini,¹⁰ Alessandro Scartabellati,¹¹ Mara Parati,¹¹ Massimiliano Villani,¹¹ Dejan Radovanovic,³ **Sara Tomassetti**,¹² Claudia Ravaglia,¹³ Venerino Poletti,¹³ Andrea Vianello,¹⁴ Anna Talia Gaccione,¹⁵ Luca Guidelli,⁵ Rita Raccanelli,¹⁵ Paolo Lucernoni,¹⁵ Donato Lacedonia,¹⁶ Maria Pia Foschino Barbaro,¹⁶ Stefano Centanni,¹⁷ Michele Mondoni,¹⁷ Matteo Davì,¹⁷ Alberto Fantin,⁹ Xueyuan Cao,¹⁸ Lucio Torelli,¹⁹ Antonella Zucchetto,²⁰ Marcella Montico,²⁰ Annalisa Casarin,²¹ Micaela

- Romagnoli,²² Stefano Gasparini,²³ Martina Bonifazi,²³ Pierlanfranco D'Agaro,²⁴ Alessandro Marcello,²⁵ Danilo Licastro,²⁶ Barbara Ruaro,¹ Maria Concetta Volpe,²⁷ Reba Umberger,¹⁸ and Marco Confalonieri. Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia. **Open Forum Infectious Diseases**, 2020. DOI: 10.1093/ofid/ofaa421
35. Sverzellati N, Silva M, Seletti V, Galeone C, Palmucci S, Piciucchi S, Vancheri C, Poletti V, **Tomassetti S**, Karwoski R, Bartholmai BJ. Stratification of long-term outcome in stable idiopathic pulmonary fibrosis by combining longitudinal computed tomography and forced vital capacity. *Eur Radiol*. 2020 Jan 31. doi: 10.1007/s00330-019-06619-5. [Epub ahead of print] PubMed PMID: 32006172.
 36. Palmucci S, Torrisi SE, Falsaperla D, Stefano A, Torcitto AG, Russo G, Pavone M, Vancheri A, Mauro LA, Grassedonio E, Sambataro G, Puglisi S, Piciucchi S, **Tomassetti S**, Poletti V, Basile A, Vancheri C. Assessment of Lung Cancer development in Idiopathic Pulmonary Fibrosis Patients Using Quantitative High-Resolution Computed Tomography: A Retrospective Analysis. **J Thorac Imaging**. 2020 Mar;35(2):115-122. doi: 10.1097/RTI.0000000000000468. PubMed PMID: 31913257.
 37. Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; **INBUILD Trial Investigators**. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. **N Engl J Med**. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29. PubMed PMID: 31566307.
 38. Vancheri C, Sebastiani A, **Tomassetti S**, Pesci A, Rogliani P, Tavanti L, Luppi F, Harari S, Rottoli P, Ghirardini A, Kirchgaessler KU, Albera C. Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis. **Respir Med**. 2019 Sep;156:78-84. doi:10.1016/j.rmed.2019.08.006. Epub 2019 Aug 13. PubMed PMID: 31445389.
 39. Walsh SLF, Lederer DJ, Ryerson CJ, Kolb M, Maher TM, Nusser R, Poletti V, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown KK, Corte TJ, Cottin V, Crestani B, Flaherty KR, Glaspole IN, Grutters J, Inoue Y, Kondoh Y, Kreuter M, Johannson KA, Ley B, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Selman M, Spagnolo P, Taniguchi H, **Tomassetti S**, Valeyre D, Wijsenbeek M, Wuyts WA, Wells AU. Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. **Am J Respir Crit Care Med**. 2019 Nov 1;200(9):1146-1153. doi:10.1164/rccm.201903-0493OC. PubMed PMID:31241357.
 40. Lim RK, Humphreys C, Morisset J, Holland AE, Johannson KA; and the **O2 Delphi Collaborators**. Oxygen in patients with fibrotic interstitial lung disease: an international Delphi survey. **Eur Respir J**. 2019 Aug 8;54(2). pii: 1900421. doi:10.1183/13993003.00421-2019. Print 2019 Aug. PubMed PMID: 31097522.
 41. Moore C, Blumhagen RZ, Yang IV, Walts A, Powers J, Walker T, Bishop M, Russell P, Vestal B, Cardwell J, Markin CR, Mathai SK, Schwarz MI, Steele MP, Lee J, Brown KK, Loyd JE, Crapo JD, Silverman EK, Cho MH, James JA, Guthridge JM, Cogan JD, Kropski JA, Swigris JJ, Bair C, Kim DS, Ji W, Kim H, Song JW, Maier LA, Pacheco KA, Hirani N, Poon AS, Li F, Jenkins RG, Braybrooke R, Saini G, Maher TMMolyneaux PL, Saunders P, Zhang Y, Gibson KF, Kass DJ, Rojas M, Sembrat J, Wolters PJ, Collard HR, Sundry JS, O'Riordan T, Streck ME, Noth I, Ma SF, Porteous MK, Kreider ME, Patel NB, Inoue Y, Hirose M, Arai T, Akagawa S, Eickelberg O, Fernandez IE, Behr J, Mogulkoc N, Corte TJ, Glaspole I, **Tomassetti S**, Ravaglia C, Poletti V, Crestani B, Borie R, Kannengiesser C, Parfrey H, Fiddler C, Rassel DMolina-Molina M, Machahua C, Worboys AM, Gudmundsson G, Isaksson HJ, Lederer DJ, Podolanczuk AJ, Montesi SB, Bendstrup E, Danchel V, Selman M, Pardo A, Henry MT, Keane MP, Doran P, Vašáková M, Sterclova M, Ryerson CJ, Wilcox PG, Okamoto T, Furusawa H, Miyazaki Y, Laurent G, Baltic S, Prele C, Moodley Y, Shea BS, Ohta K, Suzukawa M, Narumoto O, Nathan SD, Venuto DC, Woldehanna ML, Kokturk N, de Andrade JA, Luckhardt

- T, Kulkarni T, Bonella F, Donnelly SC, McElroy A, Armstrong ME, Aranda A, Carbone RG, Puppo F, Beckman KB, Nickerson DA, Fingerlin TE, Schwartz DA. Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. **Am J Respir Crit Care Med.** 2019 Jul 15;200(2):199-208. doi:10.1164/rccm.201810-1891OC. PubMed PMID: 31034279; PubMed Central PMCID:PMC6635791.
42. Ravaglia C, Bosi M, Wells AU, Gurioli C, Gurioli C, Dubini A, Piciocchi S, Puglisi S, Mascetti S, Arcadu A, **Tomassetti S**, Poletti V. Idiopathic pulmonary fibrosis: prognostic impact of histologic honeycombing in transbronchial lung cryobiopsy. **Multidiscip Respir Med.** 2019 Feb 8;14:3. doi: 10.1186/s40248-019-0170-y. eCollection 2019. PubMed PMID: 30774952; PubMed Central PMCID: PMC6367843.
43. Bosi M, Milioli G, Parrino L, Fanfulla F, **Tomassetti S**, Melpignano A, Trippi I, Vaudano AE, Ravaglia C, Mascetti S, Poletti V. Quality of life in idiopathic pulmonary fibrosis: The impact of sleep disordered breathing. **Respir Med.** 2019 Feb;147:51-57. doi: 10.1016/j.rmed.2018.12.018. Epub 2019 Jan 10. PubMed PMID:30704699.
44. Harari S, Caminati A, Confalonieri M, Poletti V, Vancheri C, Pesci A, Rogliani P, Luppi F, Agostini C, Rottoli P, Sanduzzi Zamparelli A, Sebastiani A, Della Porta R, Salton F, Messori B, **Tomassetti S**, Rosso R, Biffi A, Puxeddu E, Cerri S, Cinetto F, Refini RM, Bocchino M, Di Michele L, Specchia C, Albera C; ILDINET (Interstitial Lung Diseases Italian Network). The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone. **Clin Respir J.** 2019 Mar;13(3):166-173. doi: 10.1111/crj.12999. PubMed PMID: 30675755.
45. Ravaglia C, Wells AU, **Tomassetti S**, Gurioli C, Gurioli C, Dubini A, Cavazza A, Colby TV, Piciocchi S, Puglisi S, Bosi M, Poletti V. Diagnostic yield and risk/benefit analysis of transbronchial lung cryobiopsy in diffuse parenchymal lung diseases: a large cohort of 699 patients. **BMC Pulm Med.** 2019 Jan 16;19(1):16. doi: 10.1186/s12890-019-0780-3. PubMed PMID: 30651103; PubMed Central PMCID: PMC6335717.
46. Cottin V, Koschel D, Günther A, Albera C, Azuma A, Sköld CM, **Tomassetti S**, Hormel P, Stauffer JL, Strombom I, Kirchgaessler KU, Maher TM. Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study. **ERJ Open Res.** 2018 Oct 19;4(4). pii: 00084-2018. doi: 10.1183/23120541.00084-2018. eCollection 2018 Oct. PubMed PMID: 30364407; PubMed Central PMCID: PMC6194203.
47. Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, Quaresima M, Stowasser S, Martinez FJ; **INSTAGE Investigators**. Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. **N Engl J Med.** 2018 Nov 1;379(18):1722-1731. doi: 10.1056/NEJMoa1811737. Epub 2018 Sep 15. PubMed PMID: 30220235.
48. Harari S, Caminati A, Poletti V, Confalonieri M, Gasparini S, Lacedonia D, Luppi F, Pesci A, Sebastiani A, Spagnolo P, Vancheri C, Balestro E, Bonifazi M, Cerri S, De Giacomo F, Della Porta R, Foschino Barbaro MP, Fui A, Pasquinelli P, Rosso R, **Tomassetti S**, Specchia C, Rottoli P for the ILDINET (Interstitial Lung Diseases Italian Network). A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis. **Respiration.** 2018;95(6):433-440. doi: 10.1159/000487711. Epub 2018 Mar 27. PubMed PMID: 29587263.
49. Sverzellati N, Odone A, Silva M, Polverosi R, Florio C, Cardinale L, Cortese G, Addonizio G, Zompatori M, Dalpiaz G, Piciocchi S, Larici AR; Italian Structured Report on **Fibrosing Lung Disease Consort**. Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist. **Radiol Med.** 2018 Apr;123(4):245-253. doi: 10.1007/s11547-017-0835-6. Epub 2017 Dec 11. PubMed PMID: 29230680; PubMed Central PMCID: PMC5849634.
50. Morisset J, Johannson KA, Jones KD, Wolters PJ, Collard HR, Walsh SLF, Ley B; **HP Delphi Collaborators**. Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis:

- An International Modified Delphi Survey. ***Am J Respir Crit Care Med***. 2017 Nov 27. doi: 10.1164/rccm.201710-1986OC. [Epub ahead of print] PubMed PMID: 29172641.
51. Bosi M, Milioli G, Fanfulla F, **Tomassetti S**, Ryu JH, Parrino L, Riccardi S, Melpignano A, Vaudano AE, Ravaglia C, Tantalocco P, Rossi A, Poletti V. OSA and Prolonged Oxygen Desaturation During Sleep are Strong Predictors of Poor Outcome in IPF. ***Lung***. 2017 Oct;195(5):643-651.
 52. Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown K, Calandriello L, Corte TJ, Cottin V, Crestani B, Flaherty K, Glaspole I, Grutters J, Inoue Y, Kokosi M, Kondoh Y, Kouranos V, Kreuter M, Johannson K, Judge E, Ley B, Margaritopoulos G, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Ryerson CJ, Selman M, Spagnolo P, Taniguchi H, **Tomassetti S**, Valeyre D, Wijsenbeek M, Wuyts W, Hansell D, Wells A; IPF Project Consortium. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. ***Eur Respir J***. 2017 Aug 31;50(2).
 53. Ravaglia C, Wells AU, **Tomassetti S**, Dubini A, Cavazza A, Piciocchi S, Sverzellati N, Gurioli C, Gurioli C, Costabel U, Tantalocco P, Ryu JH, Chilosi M, Poletti V. Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Disease: Comparison between Biopsy from 1 Segment and Biopsy from 2 Segments - Diagnostic Yield and Complications. ***Respiration***. 2017;93(4):285-292. doi: 10.1159/000456671. Epub 2017 Mar 1.
 54. Viglietta L, Inchingolo R, Pavano C, **Tomassetti S**, Piciocchi S, Smargiassi A, Ravaglia C, Dubini A, Gurioli C, Gurioli C, Poletti V. Ultrasonography for the Diagnosis of Pneumothorax after Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Diseases. ***Respiration***. 2017;94(2):232-236.
 55. Calìo A, Lever V, Rossi A, Gilioli E, Brunelli M, Dubini A, **Tomassetti S**, Piciocchi S, Nottegar A, Rossi G, Kambouchner M, Cancellieri A, Barbareschi M, Pelosi G, Doglioni C, Cavazza A, Carella R, Graziano P, Murer B, Poletti V, Chilosi M. Increased frequency of bronchiolar histotypes in lung carcinomas associated with idiopathic pulmonary fibrosis. ***Histopathology***. 2017 May 30.
 56. Mariani F, Gatti B, Rocca A, Bonifazi F, Cavazza A, Fanti S, **Tomassetti S**, Piciocchi S, Poletti V, Zompatori M. Pleuroparenchymal fibroelastosis: the prevalence of secondary forms in hematopoietic stem cell and lung transplantation recipients. ***Diagn Interv Radiol***. 2016 Jul 26.
 57. **Tomassetti S**, Wells AU, Costabel U, Cavazza A, Colby TV, Rossi G, Sverzellati N, Carloni A, Carretta E, Buccioli M, Tantalocco P, Ravaglia C, Gurioli C, Dubini A, Piciocchi S, Ryu JH, Poletti V. Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis. ***Am J Respir Crit Care Med***. 2016 Apr 1;193(7):745-52.
 58. Ravaglia C, Bonifazi M, Wells AU, **Tomassetti S**, Gurioli C, Piciocchi S, Dubini A, Tantalocco P, Sanna S, Negri E, Tramacere I, Ventura VA, Cavazza A, Rossi A, Chilosi M, La Vecchia C, Gasparini S, Poletti V. Safety and Diagnostic Yield of Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Diseases: A Comparative Study versus Video-Assisted Thoracoscopic Lung Biopsy and a Systematic Review of the Literature. ***Respiration***. 2016;91(3):215-27.
 59. Harari S, Caminati A, Albera C, Vancheri C, Poletti V, Pesci A, Luppi F, Saltini C, Agostini C, Bargagli E, Sebastiani A, Sanduzzi A, Giunta V, Della Porta R, Bandelli GP, Puglisi S, **Tomassetti S**, Biffi A, Cerri S, Mari A, Cinetto F, Tirelli F, Farinelli G, Bocchino M, Specchia C, Confalonieri M. Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study. ***Respir Med***. 2015 Jul;109(7):904-13.
 60. **Tomassetti S**, Gurioli C, Ryu J, Decker P, Ravaglia C, Tantalocco P, Buccioli M, Piciocchi S, Sverzellati N, Dubini A, Gavelli G, Chilosi M, Poletti V. The impact of lung cancer on survival of Idiopathic Pulmonary Fibrosis. ***Chest***. 2015 Jan;147(1):157-64.

61. Ravaglia C, **Tomassetti S**, Gurioli Ch, Piciucchi S, Dubini A, Gurioli C, Casoni GL, Romagnoli M, Carloni A, Tantalocco P, Buccioli M, Poletti V. Features and outcome of familial idiopathic pulmonary fibrosis. **Sarcoidosis Vasc Diffuse Lung Dis.** 2014 Apr 18;31(1):28-36.
62. GL Casoni^{1*}, **S Tomassetti***, A Cavazza, TV Colby, A Dubini, JH Ryu, E Carretta, P Tantalocco, S Piciucchi, C Ravaglia, C Gurioli, M Romagnoli, C Gurioli, M Chilosi, V Poletti. Transbronchial Lung Cryobiopsy in The Diagnosis of Fibrotic Interstitial Lung Diseases **PLoS One.** 2014 Feb 28;9(2):e86716.
63. Chilosi M, Facchetti F, Caliò A, Zamò A, Brunelli M, Martignoni G, Rossi A, Montagna L, Piccoli P, Dubini A, Tironi A, **Tomassetti S**, Poletti V, Doglioni C. Oncogene induced senescence distinguishes indolent from aggressive forms of pulmonary and non-pulmonary Langerhans' cell histiocytosis. **Leuk Lymphoma.** 2014 Jan 29.
64. Ulivi P, Casoni GL, Foschi G, Scarpi E, **Tomassetti S**, Romagnoli M, Ravaglia C, Mengozzi M, Zoli W, Poletti V. MMP-7 and free circulating DNA serum levels in early NSCLC and idiopathic interstitial pneumonia patients. *Int J Mol Sci.* 2013 Dec 11;14(12):24097-112.
65. **S. Tomassetti**, J.H. Ryu, C. Gurioli, C. Ravaglia, M. Buccioli, P. Tantalocco, P.A. Decker, A. Cavazza, A. Dubini, V. Agnoletti, C. Gurioli, G.L. Casoni, M. Romagnoli, V. Poletti The effect of anticoagulant therapy for idiopathic pulmonary fibrosis in real life practice. *Sarcoidosis Vasc Diffuse Lung Dis.* 2013 Aug 1;30(2):121-127.
66. **Tomassetti S**, Cavazza A, Colby TV, Ryu JH, Nanni O, Scarpi E, Tantalocco P, Buccioli M, Dubini A, Piciucchi S, Ravaglia C, Gurioli C, Casoni GL, Gurioli C, Romagnoli M, Poletti V. Transbronchial biopsy is useful in predicting UIP pattern. *Respir Res.* 2012 Oct 29;13:96
67. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, **Tomassetti S**, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE Jr, Collard HR. A multidimensional index and staging system for idiopathic pulmonary fibrosis. *Ann Intern Med.* 2012 May 15;156(10):684-91.
68. Piciucchi S, **Tomassetti S**, Casoni G, Sverzellati N, Carloni A, Dubini A, Gavelli G, Cavazza A, Chilosi M, Poletti V. High resolution CT and histological findings in idiopathic pleuroparenchymal fibroelastosis: features and differential diagnosis. *Respir Res.* 2011 Aug 23;12:111.
69. Casoni GL, Cordeiro CR Jr, **Tomassetti S**, Romagnoli M, Chilosi M, Cancellieri A, Gurioli C, Poletti V. The transbronchial lung biopsy for diagnosis of diffuse parenchymal lung disease; *Rev Port Pneumol.* 2011 Jun 28.
70. **Tomassetti S**, Carloni A, Chilosi M, Maffè A, Ungari S, Sverzellati N, Gurioli C, Casoni G, Romagnoli M, Gurioli C, Ravaglia C, Poletti V. Pulmonary features of Birt-Hogg-Dubé syndrome: cystic lesions and pulmonary histiocytoma. *Respir Med.* 2011 May;105(5):768-74. Epub 2011 Feb 26.
71. Romagnoli M, Nannini C, Piciucchi S, Girelli F, Gurioli C, Casoni G, Ravaglia C, **Tomassetti S**, Gurioli C, Gavelli G, Carloni A, Dubini A, Cantini F, Chilosi M, Poletti V. Idiopathic NSIP: an interstitial lung disease associated with autoimmune disorders? *Eur Respir J.* 2011 Jan 27.
72. Reghellin D, Poletti V, **Tomassetti S**, Dubini A, Cavazza A, Rossi G, Lestani M, Pedron S, Daniele I, Montagna L, Murer B, Chilosi M. Cathepsin-K is a sensitive immunohistochemical marker for detection of micro-granulomas in hypersensitivity pneumonitis. *Sarcoidosis Vasc Diffuse Lung Dis.* 2010 Jul;27(1):57-63.
73. Casoni GL, Ulivi P, Mercatali L, Chilosi M, **Tomassetti S**, Romagnoli M, Ravaglia C, Gurioli C, Gurioli C, Zoli W, Silvestrini R, Poletti V. Increased levels of free circulating DNA in patients with idiopathic pulmonary fibrosis. *Int J Biol Markers.* 2010 Oct-Dec;25(4):229-35.
74. Maffè A, Toschi B, Circo G, Giachino D, Giglio S, Rizzo A, Carloni A, Poletti V, **Tomassetti S**, Ginardi C, Ungari S, Genuardi M. Constitutional FLCN mutations in patients with suspected Birt-Hogg-Dubé syndrome ascertained for non-cutaneous manifestations. *Clin Genet.* 2010 Jun 7.

75. Sverzellati N, Wells AU, **Tomassetti S**, Desai SR, Copley SJ, Aziz ZA, Zompatori M, Chilosi M, Nicholson AG, Poletti V, Hansell DM. Biopsy proved idiopathic pulmonary fibrosis: spectrum of nondiagnostic thin section CT diagnoses. *Radiology*. 2010 Mar;254(3):957-64
76. G Marchesini, M Brizi, G Bianchi, **S Tomassetti**, E Bugianesi, M Lenzi, S Natale, AJ McCullough, G Forlani, N Melchionda. Non-alcoholic fatty liver disease: a feature of the metabolic syndrome. *Diabetes* 2001; 50:1844-50

Altre pubblicazioni su riviste peer reviewer con IF (review, case reports and case series, report of new methods, guidelines and consensus documents)

1. Drent M, Russell AM, Saketkoo LA, Spagnolo P, Veltkamp M, Wells AU; representatives of the sarcoidosis community. Breaking barriers: holistic assessment of ability to work in patients with sarcoidosis. *Lancet Respir Med*. 2024 Nov;12(11):848-851. doi: 10.1016/S2213-2600(24)00297-2. Epub 2024 Oct 16
2. Damiani A, Orlandi M, Bruni C, Bandini G, Lepri G, Scaletti C, Ravaglia C, Frassanito F, Guiducci S, Moggi-Pignone A, Matucci-Cerinic M, Poletti V, Tofani L, Colby TV, Randone SB, **Tomassetti S**. The role of lung biopsy for diagnosis and prognosis of interstitial lung disease in systemic sclerosis: a systematic literature review. *Respir Res*. 2024 Mar 23;25(1):138. PMID: 38521926; PMCID: PMC10960984.
3. **Tomassetti S**, Ciani L, Luzzi V, Gori L, Trigiani M, Giuntoli L, Lavorini F, Poletti V, Ravaglia C, Torrego A, Maldonado F, Lentz R, Annunziato F, Maggi L, Rossolini GM, Pollini S, Para O, Ciurleo G, Casini A, Rasero L, Bartoloni A, Spinicci M, Munavvar M, Gasparini S, Comin C, Cerinic MM, Peired A, Henket M, Ernst B, Louis R, Corhay JL, Nardi C, Guiot J, Lepri G, Bruni C, Tofani L, Moggi-Pignone A, Orlandi M, Hughes M, Del Galdo F, Irace R, Distler O, Riccieri V, Allanore Y, Gheorghiu AM, Siegert E, De Vries-Bouwstra J, Hachulla E, Tikly M, Damjanov N, Spertini F, Mouthon L, Hoffmann-Vold AM, Gabrielli A, Guiducci S, Matucci-Cerinic M, Furst D, Bellando-Randone S. Utility of bronchoalveolar lavage for COVID-19: a perspective from the Dragon consortium. *Front Med (Lausanne)*. 2024;11:1259570. PMID: 38337811; PMCID: PMC10855256.
4. Orlandi M, Meliante LA, Damiani A, Tofani L, Bruni C, Guiducci S, Matucci-Cerinic M, Bellando-Randone S, **Tomassetti S**. The Role of Bronchoalveolar Lavage in Systemic Sclerosis Interstitial Lung Disease: A Systematic Literature Review. *Pharmaceuticals* (Basel). 2022 Dec 19;15(12):1584. doi: 10.3390/ph15121584. PMID:36559035; PMCID: PMC9781787.
5. Korevaar DA, Colella S, Fally M, Camuset J, Colby TV, Hagemeyer L, Hetzel J, Maldonado F, Morais A, Ravaglia C, Spijker R, **Tomassetti S**, Troy LK, Verschakelen JA, Wells AU, Tonia T, Annema JT, Poletti V. **European Respiratory Society guidelines** on transbronchial lung cryobiopsy in the diagnosis of interstitial lung diseases. *Eur Respir J*. 2022 Nov 10;60(5):2200425. doi: 10.1183/13993003.00425-2022. PMID: 35710261.
6. Farina N, Benanti G, De Luca G, Palmisano A, Peretto G, **Tomassetti S**, Giorgione V, Forma O, Esposito A, Danese S, Dagna L, Matucci-Cerinic M, Campochiaro C. Review. The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis. *J Multidiscip Healthc*. 2022 Apr 20;15:815-824. doi:10.2147/JMDH.S295478. PMID: 35480063; PMCID: PMC9035450.
7. **Tomassetti S**, Poletti V, Ravaglia C, Sverzellati N, Piciucchi S, Cozzi D, Luzzi V, Comin C, Wells AU. Review. Incidental discovery of interstitial lung disease: diagnostic approach, surveillance and perspectives. *Eur Respir Rev*. 2022 Apr 13;31(164):210206. doi: 10.1183/16000617.0206-2021. Erratum in: *Eur Respir Rev*. 2022 May 25;31(164): PMID: 35418487; PMCID: PMC9488620.
8. Cottin V, **Tomassetti S**, Valenzuela C, Walsh SLF, Antoniou KM, Bonella F, Brown KK, Collard HR, Corte TJ, Flaherty KR, Johannson KA, Kolb M, Kreuter M, Inoue Y, Jenkins RG,

- Lee JS, Lynch DA, Maher TM, Martinez FJ, Molina-Molina M, Myers JL, Nathan SD, Poletti V, Quadrelli S, Raghu G, Rajan SK, Ravaglia C, Remy-Jardin M, Renzoni E, Richeldi LK, Spagnolo P, Troy L, Wijsenbeek M, Wilson KC, Wuyts W, Wells AU, Ryerson CJ. Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. **Am J Respir Crit Care Med.** 2022 Aug 1;206(3):247-259. doi:10.1164/rccm.202111-2607PP. PMID: 35353660.
9. Landini N, Orlandi M, Bruni C, Carlesi E, Nardi C, Calistri L, Morana G, **Tomassetti S**, Colagrande S, Matucci-Cerinic M. Computed Tomography Predictors of Mortality or Disease Progression in Systemic Sclerosis-Interstitial Lung Disease: A Systematic Review. **Front Med (Lausanne).** 2022 Jan 27;8:807982. doi: 10.3389/fmed.2021.807982. PMID: 35155484; PMCID: PMC8829727.
 10. **Sara Tomassetti**, Thomas V. Colby, Athol U. Wells, Venerino Poletti, Ulrich Costabel and Marco Matucci-Cerinic. Bronchoalveolar lavage and lung biopsy in connective tissue diseases, to do or not to do? *Ther Adv Musculoskel Dis* 2021, Vol. 13: 1–21 DOI: 10.1177/1759720X2111059605
 11. **Tomassetti S**, Maldonado F, Poletti V. COUNTERPOINT: Should Surgical Lung Biopsy Still Be Performed for Interstitial Lung Disease Evaluation? No. *Chest.* 2021 Dec;160(6):2011-2014. doi: 10.1016/j.chest.2021.06.061. PMID: 34872666
 12. **Tomassetti S**, Maldonado F, Poletti V. Rebuttal From Dr Tomassetti et al. *Chest.* 2021 Dec;160(6):2015-2016. doi: 10.1016/j.chest.2021.06.059. PMID: 34872668
 13. Cottin V, Richeldi L, Rosas I, Otaola M, Song JW, **Tomassetti S**, Wijsenbeek M, Schmitz M, Coeck C, Stowasser S, Schlenker-Herceg R, Kolb M; INBUILD Trial Investigators. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. *Respir Res.* 2021 Mar 16;22(1):84. doi: 10.1186/s12931-021-01668-1. PMID: 33726766
 14. Kalluri M, Luppi F, Vancheri A, Vancheri C, Balestro E, Varone F, Mogulkoc N, Cacopardo G, Bargagli E, Renzoni E, Torrisi S, Calvello M, Libra A, Pavone M, Bonella F, Cottin V, Valenzuela C, Wijsenbeek M, Bendstrup E; 3rd International Summit for ILD (ISILD), **Erice collaborators** listed below. Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here? *Eur Respir Rev.* 2021 May 25;30(160):210026. doi: 10.1183/16000617.0026-2021. Print 2021 Jun 30. PMID: 34039675
 15. Orlandi M, Landini N, Bruni C, Sambataro G, Nardi C, Bargagli E, **Tomassetti S**, Occhipinti M, Bellando Randone S, Guiducci S, Vancheri C, Colagrande S, Matucci-Cerinic M. Pleuroparenchymal fibroelastosis in rheumatic autoimmune diseases: a systematic literature review. *Rheumatology (Oxford).* 2020 Dec 1;59(12):3645-3656. doi: 10.1093/rheumatology/keaa451. PMID: 33313932
 16. George PM, Spagnolo P, Kreuter M, Altinisik G, Bonifazi M, Martinez FJ, Molyneaux PL, Renzoni EA, Richeldi L, **Tomassetti S**, Valenzuela C, Vancheri C, Varone F, Cottin V, Costabel U; Erice ILD working group. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. **Lancet Respir Med.** 2020 Sep;8(9):925-934. doi: 10.1016/S2213-2600(20)30355-6. PMID: 32890499
 17. Carriço F, Gurioli C, Piciucchi S, Dubini A, **Tomassetti S**, Poletti V. Pulmonary vein stenosis mimicking interstitial lung disease. **Pulmonology.** 2020 Jun 19;S2531-0437(20)30126-4. doi: 10.1016/j.pulmoe.2020.05.010. Online ahead of print. PMID: 32571674
 18. Inoue Y, Kaner RJ, Guiot J, Maher TM, **Tomassetti S**, Moiseev S, Kuwana M, Brown KK. Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype. **Chest.** 2020 Aug;158(2):646-659. doi: 10.1016/j.chest.2020.03.037. Epub 2020 Apr 5. PMID: 32268131
 19. Cavazza A, Colby TV, Dubini A, **Tomassetti S**, Ravaglia C, Poletti V, Mengoli MC, Tagliavini E, Rossi G. Transbronchial Cryobiopsy in the Diagnosis of Diffuse Lung Disease. **Surg Pathol Clin.** 2020 Mar;13(1):197-208. doi:10.1016/j.path.2019.11.004. Review. PubMed PMID: 32005433.

20. Poletti V, **Tomassetti S**, Gurioli C, Gurioli C, Asioli S, Piciucchi S, Dubini A, Ravaglia C, Kronborg-White S. An HIV + patient with visceral enlarged lymphnodes. **Eur Clin Respir J**. 2019 Apr 1;6(1):1591843. doi:10.1080/20018525.2019.1591843. eCollection 2019. PubMed PMID: 30988895; PubMedCentral PMCID: PMC6450598
21. Ravaglia C, Rossi G, **Tomassetti S**, Dubini A, Piciucchi S, Chilosi M, Cavazza A, Bendstrup E, Kronborg-White SB, Folkersen B, Colella S, Madsen LB, Poletti V. Report Standardization in Transbronchial Lung Cryobiopsy. **Arch Pathol Lab Med**. 2019 Apr;143(4):416-417. doi: 10.5858/arpa.2018-0438-LE. PubMed PMID: 30920865.
22. Bargagli E, Rottoli P, Torricelli E, Allegrini C, Dubini A, Bennett D, Luzzi L, Spina D, Poletti V, **Tomassetti S**. Airway-Centered Pleuroparenchymal Fibroelastosis Associated with Non-Necrotizing Granulomas: A Rare New Entity. **Pathobiology**. 2018;85(5-6):276-279. doi: 10.1159/000492431. Epub 2018 Sep 17. PubMed PMID: 30223268.
23. Kronborg-White S, Ravaglia C, Dubini A, Piciucchi S, **Tomassetti S**, Bendstrup E, Poletti V. Cryobiopsies are diagnostic in Pleuroparenchymal and Airway-centered Fibroelastosis. **Respir Res**. 2018 Jul 13;19(1):135. doi: 10.1186/s12931-018-0839-3. PubMed PMID: 30005615; PubMed Central PMCID: PMC6045856.
24. Hetzel J, Maldonado F, Ravaglia C, Wells AU, Colby TV, **Tomassetti S**, Ryu JH, Fruchter O, Piciucchi S, Dubini A, Cavazza A, Chilosi M, Sverzellati N, Valeyre D, Leduc D, Walsh SLF, Gasparini S, Hetzel M, Hagemeyer L, Haentschel M, Eberhardt R, Darwiche K, Yarmus LB, Torrego A, Krishna G, Shah PL, Annema JT, Herth FJF, Poletti V. Transbronchial Cryobiopsies for the Diagnosis of Diffuse Parenchymal Lung Diseases: Expert Statement from the Cryobiopsy Working Group on Safety and Utility and a Call for Standardization of the Procedure. **Respiration**. 2018;95(3):188-200. doi: 10.1159/000484055. Epub 2018 Jan 9. PubMed PMID: 29316560.
25. Poletti V, Ravaglia C, Dubini A, Piciucchi S, Rossi G, Kronborg-White S, **Tomassetti S**. How might transbronchial cryobiopsy improve diagnosis and treatment of diffuse parenchymal lung disease patients? **Expert Rev Respir Med**. 2017 Dec;11(12):913-917. doi: 10.1080/17476348.2017.1395283. Epub 2017 Oct 25. PubMed PMID: 29050527.
26. **Tomassetti S**, Ravaglia C, Poletti V. Diffuse parenchymal lung disease. **Eur Respir Rev**. 2017 Apr 26;26(144).
27. Hetzel J, Maldonado F, Ravaglia C, Wells AU, Colby TV, **Tomassetti S**, Ryu JH, Fruchter O, Piciucchi S, Dubini A, Cavazza A, Chilosi M, Sverzellati N, Valeyre D, Leduc D, Walsh SLF, Gasparini S, Hetzel M, Hagemeyer L, Haentschel M, Eberhardt R, Darwiche K, Yarmus LB, Torrego A, Krishna G, Shah PL, Annema JT, Herth FJF, Poletti V. Transbronchial Cryobiopsies for the Diagnosis of Diffuse Parenchymal Lung Diseases: Expert Statement from the Cryobiopsy Working Group on Safety and Utility and a Call for Standardization of the Procedure. **Respiration**. 2018;95(3):188-200.
28. Colella S, Clementsen PF, Gurioli C, Gurioli CH, Ravaglia C, **Tomassetti S**, Rossi A, Piciucchi S, Dubini A, Poletti V. Endobronchial-ultrasound needle aspiration and endoscopic ultrasound-fine-needle aspiration in thoracic diseases. **Pathologica**. 2016 Jun;108(2):59-79.
29. Sverzellati N, Odone A, Silva M, Polverosi R, Florio C, Cardinale L, Cortese G, Addonisio G, Zompatori M, Dalpiaz G, Piciucchi S, Larici AR; **Italian Structured Report on Fibrosing Lung Disease Consort**. Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist. **Radiol Med**. 2018 Apr;123(4):245-253.
30. Poletti V, Ravaglia C, Dubini A, Piciucchi S, Rossi G, Kronborg-White S, **Tomassetti S**. How might transbronchial cryobiopsy improve diagnosis and treatment of diffuse parenchymal lung disease patients? **Expert Rev Respir Med**. 2017 Dec;11(12):913-917.
31. Bosi M, Ravaglia C, **Tomassetti S**, et al. La sindrome delle apnee ostruttive nel sonno nel paziente con stroke *Rassegna* vol 31 p 14-18 2016
32. **Tomassetti S**. Correvva l'anno 2016. **Rassegna Mal App Resp**, 2016 in press

33. **Tomassetti S**, Ravaglia C, Poletti V. Diffuse parenchymal lung disease. **Eur Resp Rev**, 2016 in press
34. Piciucchi S, Dubini A, **Tomassetti S**, Sanna S, Ravaglia C, Carloni A, Gurioli C, Gurioli C, Colby TV, Poletti V. Angiosarcoma in the chest: radiologic-pathologic correlation: Case report. **Medicine (Baltimore)**. 2016 Nov;95(48):e5348.
35. Colby TV, **Tomassetti S**, Cavazza A, Dubini A, Poletti V. Transbronchial Cryobiopsy in Diffuse Lung Disease: Update for the Pathologist. **Arch Pathol Lab Med**. 2016 Sep 2.
36. Varone F, Mastrobattista A, Franchi P, Viglietta L, Poletti V, **Tomassetti S**, Dubini A, Tagliaboschi L, Calandriello L, Farchione A, Larici AR. Pulmonary fibrolysis in a patient with idiopathic pulmonary fibrosis: improvement of clinical and radiological pattern after treatment with pirfenidone. **Clin Respir J**. 2016 Jun 20. doi: 10.1111/crj.12515.
37. Piciucchi S, **Tomassetti S**, Ravaglia C, Gurioli C, Gurioli C, Dubini A, Carloni A, Chilosi M, Colby TV, Poletti V. From "traction bronchiectasis" to honeycombing in idiopathic pulmonary fibrosis: A spectrum of bronchiolar remodeling also in radiology? **BMC Pulm Med**. 2016 May 23;16(1):87.
38. **Tomassetti S**, Ryu JH, Piciucchi S, Chilosi M, Poletti V. Nonspecific Interstitial Pneumonia: What Is the Optimal Approach to Management? **Semin Respir Crit Care Med**. 2016 Jun;37(3):378-94.
39. Poletti V, Ravaglia C, Gurioli C, Piciucchi S, Dubini A, Cavazza A, Chilosi M, Rossi A, **Tomassetti S**. Invasive diagnostic techniques in idiopathic interstitial pneumonias. **Respirology**. 2016 Jan;21(1):44-50.
40. **Tomassetti S**, Ryu JH, Poletti V. Staging systems and disease severity assessment in interstitial lung diseases. *Curr Opin Pulm Med*. 2015 Sep;21(5):463-9.
41. Milioli G, Bosi M, Poletti V, **Tomassetti S**, Grassi A, Riccardi S, Terzano MG, Parrino L. Sleep and respiratory sleep disorders in idiopathic pulmonary fibrosis. *Sleep Med Rev*. 2016 Apr;26:57-63.
42. Poletti V, Ravaglia C, **Tomassetti S**. Transbronchial cryobiopsy in diffuse parenchymal lung diseases. *Curr Opin Pulm Med*. 2016 May;22(3):289-96.
43. **S Tomassetti**. Correvia l'anno 2015, pneumopatie infiltrative diffuse e patologia del circolo polmonare. Rassegna di Patologia dell'Apparato Respiratorio, 2016
44. Pietrangeli V, Piciucchi S, **Tomassetti S**, Ravaglia C, Gurioli C, Gurioli C, Cavazza A, Dubini A, Poletti V. Diffuse Neuroendocrine Hyperplasia with Obliterative Bronchiolitis and Usual Interstitial Pneumonia: An Unusual "Headcheese Pattern" with Nodules. *Lung*. 2015 Oct 7. [Epub ahead of print]
45. Antoniou KM, **Tomassetti S**, Tsitoura E, Vancheri C. Idiopathic pulmonary fibrosis and lung cancer: a clinical and pathogenesis update. *Curr Opin Pulm Med*. 2015 Nov;21(6):626-33.
46. **Tomassetti S**, Piciucchi S, Tantalocco P, Dubini A, Poletti V. The multidisciplinary approach in the diagnosis of idiopathic pulmonary fibrosis: a patient case-based review. *Eur Respir Rev*. 2015 Mar;24(135):69-77.
47. Piciucchi S, Dubini A, **Tomassetti S**, Casoni G, Ravaglia C, Poletti V. A case of amiodarone-induced acute fibrinous and organizing pneumonia mimicking mesothelioma. *Am J Respir Crit Care Med*. 2015 Jan 1;191(1):104-6.
48. **Sara Tomassetti**, Carlo Albera Domenico Aronne Marco Confalonieri Sergio Harari Maurizio Luisetti Venerino Poletti1 Luca Richeldi7 Paola Rottoli Cesare Saltini9 Carlo Vancheri1 Patrizio Vitulo. Alberto Pesci. Documento AIPO-SIMeR sulla IPF. Rassegna di Mal App Resp, 2015
49. **S Tomassetti**. Correvia l'anno 2014, pneumopatie infiltrative diffuse e patologia del circolo polmonare. Rassegna di Patologia dell'Apparato Respiratorio, 2015
50. Poletti V, Ravaglia C, **Tomassetti S**. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. *Expert Rev Respir Med*. 2014 Oct;8(5):539-45.

51. V Poletti, GL Casoni, C Gurioli, JH Ryu, **S Tomassetti**. Lung cryobiopsies: a paradigm shift in diagnostic bronchoscopy? *Respirology*. 2014 Jul;19(5):645-54.
52. **S Tomassetti**. Corvea l'anno 2013, pneumopatie infiltrative diffuse e patologia del circolo polmonare. Rassegna di Patologia dell'Apparato Respiratorio, 2014
53. KM. Antoniou, GA. Margaritopoulos, **Sara Tomassetti**, F Bonella, U. Costabel and V. Poletti. INTERSTITIAL LUNG DISEASE: Year In Review. *Eur Respir Rev*. 2014 Mar 1;23(131):40-54.
54. V Poletti, C Ravaglia, **S Tomassetti**, C Gurioli, G Casoni, S Asioli, A Dubini, S Piciucchi, M Chilosi Lymphoproliferative lung disorders: clinicopathologic aspects. *Eur Respir Rev*. 2013 Dec;22(130):427-36.
55. **S Tomassetti**^[1], JH. Ryu, G Casoni, C Gurioli, C Ravaglia, M Buccioli, P Tantalocco, C. Gurioli M Romagnoli, V Poletti. Revisione critica delle Linee Guida ATS/ERS sulla fibrosi polmonare idiopatica (IPF). Critical revision of ATS / ERS Guidelines on idiopathic pulmonary fibrosis (IPF). *Rassegna di Patologia dell'Apparato Respiratorio* 2013; 28: 74-89
56. Poletti V, Ravaglia C, Buccioli M, Tantalocco P, Piciucchi S, Dubini A, Carloni A, Chilosi M, **Tomassetti S**. Idiopathic pulmonary fibrosis: diagnosis and prognostic evaluation. *Respiration*. 2013;86(1):5-12.
57. Wells AU, Behr J, Costabel U, Cottin V, Poletti V, Richeldi L; European IPF Consensus Group. Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. *Thorax*. 2012 Nov;67(11):938-40.
58. Ravaglia C, Gurioli C, **Tomassetti S**, Casoni GL, Romagnoli M, Gurioli C, Agnoletti V, Poletti V. Is medical thoracoscopy efficient in the management of multiloculated and organized thoracic empyema? *Respiration*. 2012;84(3):219-24.
59. J.H. Ryu, F. Maldonado and **S. Tomassetti** Idiopathic tracheopathies. *Eur Respir Mon* 2011. 54, 1–15.
60. Gurioli C, Ravaglia C, Romagnoli M, Casoni G, **Tomassetti S**, Nanni O, Poletti V EBUS-TBNA in mediastinal/hilar lymphadenopathies and/or masses: an Italian case series. *Clin Respir J*. 2012 Jan;6(1):3-8.
61. Casoni GL, Chilosi M, Romagnoli M, **Tomassetti S**, Poletti V. Another "chance" for interferon gamma 1b? *Sarcoidosis Vasc Diffuse Lung Dis*. 2011 Jul;28(1):79-80
62. Poletti V, Casoni G, Ravaglia C, Romagnoli M, **Tomassetti S**. Bronchoalveolar lavage. Technical notes. *Monaldi Arch Chest Dis*. 2011 Mar;75(1):42-3.
63. Gurioli C, Casoni GL, Gurioli C, **Tomassetti S**, Romagnoli M, Ravaglia C, Poletti V. Endobronchial ultrasound in Dieulafoy's disease of the bronchus: an additional application of EBUS. *Monaldi Arch Chest Dis*. 2010 Dec;73(4):166-8.
64. Chilosi M, **Tomassetti S**, Carloni A, Murer B. The pathologist's role in the diagnosis of idiopathic pulmonary fibrosis. *Pathologica*. 2010 Dec;102(6):443-52.
65. Ravaglia C, Gurioli C, Casoni G, Romagnoli M, **Tomassetti S**, Gurioli C, Corso RM, Poletti G, Dubini A, Marinou A, Poletti V. Diagnostic role of rapid on-site cytologic examination (ROSE) of broncho-alveolar lavage in ALI/ARDS. *Pathologica*. 2012 Apr;104(2):65-9.
66. Ryu JH, **Tomassetti S**, Maldonado F. Update on uncommon pleural effusions. *Respirology*. 2010 Nov 15.
67. Poletti V, **Tomassetti**. Ultrasound endoscopy (EBUS, EUS) as a sophisticated tool for morphological confirmation of sarcoidosis: do we need to find new answers for an old quest? *S. Sarcoidosis Vasc Diffuse Lung Dis*. 2010 Jul;27(1):5-6.
68. Chilosi M, **Tomassetti S**, Carloni A, Murer B. The pathologist's role in the diagnosis of idiopathic pulmonary fibrosis. *Pathologica*. 2010 Dec;102(6):443-52.
69. Casoni GL, **Tomassetti S**, Coffa A, Ravaglia C, Poletti V. Negative pressure pulmonary hemorrhage induced by a candy. *Am J Emerg Med*. 2010 Jan;28(1):112.

70. De Filippo, Ingegnoli A, Carloni A, Verardo E, Sverzellati N, Onniboni M, Corsi A, **Tomassetti S**, Mazzei M, Volterrani L, Poletti V, Zompatori M. Erdheim-Chester disease: clinical and radiological findings. *Diagnostic Radiology . Radiol Med.* 2009 Nov 14.
71. Romagnoli M, Bigliuzzi C, Casoni GL, Chilosi M, Carloni A, Dubini A, Gurioli Ch, **Tomassetti S**, Gurioli C, Poletti V. "The role of transbronchial lung biopsy for the diagnosis of diffuse drug-induced lung disease: a case series of 44 patients". *Sarcoidosis, Vasculitis and Diffuse Lung Diseases*, 2008.
72. Zinzani PL, Poletti V, Zompatori M, Tani M, Spaggiari L, **Tomassetti S**, Broccoli A, Derenzini E, Baccarani M. Bronchus-associated lymphoid tissue lymphomas: an update of a rare extranodal maltoma. *Clin Lymphoma Myeloma.* 2007 Nov;7(9):566-72.

Lettere all'Editore ed Editoriali

1. Podolanczuk AJ, Tomassetti S. Big Things Have Small Beginnings: Clinical Implications of Early Interstitial Lung Disease. *Am J Respir Crit Care Med.* 2024 Dec 15;210(12):1394-1395. doi: 10.1164/rccm.202408-1611ED.
2. Tomassetti S, Ravaglia C, Poletti V. Pinocchio and Interstitial Lung Abnormalities: Is It Just Another Lie? *Am J Respir Crit Care Med.* 2023 Dec 15;208(12):1341-1342. PMID: 37856834; PMCID: PMC10765386.
3. Piciucchi S, Fernades LS, Ravaglia C, **Tomassetti S**, Garo ML, Poletti V. Letter to the Editor. "Gallia est omnis divisa in partes tres": Is it time to divide Pleuroparenchymal Fibroelastosis in three different forms? **Pulmonology.** 2023 May 18:S2531-0437(23)00080-6. doi: 10.1016/j.pulmoe.2023.04.001. Epub ahead of print. PMID: 37210339.
4. Graziani L, Gori L, Manciuilli T, Basile G, Campolmi I, Borchì B, di Dio M, Mattei M, Ciurleo G, Ciliberti M, Malentacchi F, Coppi M, Morettini A, Parronchi P, Rossolini GM, Bartoloni A, **Tomassetti S**, Spinicci M. Research Letter. Successful use of nirmatrelvir/ritonavir in immunocompromised patients with persistent and/or relapsing COVID-19. **J Antimicrob Chemother.** 2023 Feb 1;78(2):555-558. doi: 10.1093/jac/dkac433. PMID: 36544352; PMCID: PMC9890247.
5. Benzaquen S, **Tomassetti S**. Editorial: Are we ready for prime time? **Curr Opin Pulm Med.** 2023 Jan 1;29(1):1-2. doi: 10.1097/MCP.0000000000000931. PMID: 36474460.
6. **Tomassetti S**, Wells A. Interstitial Lung Abnormalities: An Evolving Entity. **Am J Respir Crit Care Med.** 2022 Jul 15;206(2):136-137. doi: 10.1164/rccm.202204-0676ED. PMID: 35536727; PMCID: PMC9887409.
7. Benzaquen S, **Tomassetti S**. Editorial: Endobronchial valve placement for endoscopic lung volume reduction (ELVR): "the start of a new era". *Curr Opin Pulm Med.* 2022 Jan 1;28(1):1-2. doi: 10.1097/MCP.0000000000000845. PMID: 34738956
8. Poletti V, **Tomassetti S**, Ravaglia C. Editorial: Time to Trust Transbronchial Cryobiopsy in Identification of Usual Interstitial Pneumonia Pattern? *Am J Respir Crit Care Med.* 2021 May 15;203(10):1218-1220. doi: 10.1164/rccm.202012-4382ED. PMID: 33503399
9. Ravaglia C, **Tomassetti S**, Poletti V. New Idiopathic Pulmonary Fibrosis Guidelines: Are Cryobiopsy and Surgery Competitive in Clinical Practice? *Am J Respir Crit Care Med.* 2019 Mar 1;199(5):666-667. doi: 10.1164/rccm.201809-1718LE. PubMed PMID: 30566848.
10. Poletti V, **Tomassetti S**, Ravaglia C. Idiopathic Pulmonary Fibrosis. *N Engl J Med.* 2018 Aug 23;379(8):797. doi: 10.1056/NEJMc1807508. PubMed PMID: 30136550.
11. Ravaglia C, Gurioli C, Casoni GL, Romagnoli M, **Tomassetti S**, Gurioli C, Dubini A, Poletti V. Sarcoid-like lesion is a frequent benign cause of lymphadenopathy in neoplastic patients. *Eur Respir J.* 2013 Mar;41(3):754-5.
12. Piciucchi S, **Tomassetti S**, Colby TV, Poletti V. Role of fibrogenesis of gastroesophageal reflux and microaspiration in a patient with 12 years of radiologic follow-up. **Hum Pathol.** 2017 Jan;59:152-153.

13. G.Marchesini,M.Brizi,G.Bianchi,**S.Tomassetti**,M.Zoli,N.Melchionda. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358:893-4

Testi per la comunità scientifica

1. Puglisi Silvia, JH Ryu, Sara **Tomassetti** and Venerino Poletti. Multidisciplinary discussion in DPLDs. Transbronchial cryobiopsy in DPLDs. Ed Springer, 2019.
2. Puglisi Silvia, Antonella Arcadu, Claudia ravaglia, Sara **Tomassetti** and Venerino Poletti. Clinical meaning of transbronchial cryobiopsy. Transbronchial cryobiopsy in DPLDs. Ed Springer, 2019.
3. Gurioli, S. **Tomassetti**, C. Gurioli Applicazioni dell'ecografia endobronchiale [SEP] alla broncoscopia terapeutica [SEP] C. In Poletti V. and Ceron L. Diagnostica ed interventistica ultrasonografica endoscopica. Edizioni minerva Medica, 2014.
4. Poletti V, Zinzani PL, **Tomassetti S**, Chilosi M. Lymphoproliferative Lung Disorders. In : Costabel U, Du Bois RM, Egan JJ (Eds). Diffuse Parenchymal Lung Disease. Progr Respir Res, Basel, Karger 2007:307-322.

Altre pubblicazioni divulgative non-peer reviewed

1. Tomassetti S1, Ravaglia C1, Gurioli C1, Chiappalone G1, Poletti V1. Prognostic assessment in IPF. Shortness of Breath, 2015
2. S. Tomassetti. Il fumo di sigaretta e la fibrosi polmonare idiopatica [Cigarettes smoke and IPF]. In: Nuovi Orizzonti. Editor: AIPO Ricerche 2008.
3. S Tomassetti. Fibrosi polmonare Idiopatica: attuali e future prospettive terapeutiche. Lung Forum, Workbook di aggiornamento in pneumologia, Sept 2014

ENGLISH LANGUAGE PROFICIENCY CERTIFATES

IELST Academic Level

BRITISH COUNCIL, Bologna, 18th January 2014

Candidate Number 11435; Passport Number AA2422927

Results: LISTENING 8.0; READING 8.5; WRITING 7; SPEAKING 7; OVERALL 7.5.

COMPETENZE IN ANALISI STATISTICA

Competenze di statistica descrittiva ed analisi di sopravvivenza. Utilizzo software STATA vers 15. Partecipazione in qualità di discente ai corsi STATA a Pavia nei giorni 9 e 26 febbraio 2019, 6 Marzo 2019, 12 Aprile 2019, 22 Novembre 2021 (8 ore ciascuna giornata).

DICHIARAZIONE SOSTITUTIVA DELL'ATTO DI NOTORIETÀ

(Art. 47 del D.P.R. 28 dicembre 2000, n. 445)

La sottoscritta **Sara Tomassetti**, nata a **Ravenna** il **22/12/1974**, ai sensi degli articoli 46 e 47 del D.P.R. 445/2000 e consapevole delle responsabilità e delle sanzioni penali previste dall'art. 76 del medesimo D.P.R. in caso di dichiarazioni mendaci e falsità negli atti,

dichiara sotto la propria responsabilità che quanto riportato nel presente Curriculum Vitae corrisponde al vero.

Luogo e data: Firenze 10-3-2026

Firma autografa o firma digitale: